UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 Washington,
D.C. 20549

 FORM

 ANNUAL
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended June 30, 2024

 TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 For
the transition period from
to

 Commission
file number: 000-27873

Great Health

 (Exact
name of registrant as specified in its charter)

 Wyoming

 98-0178621

 (State or other jurisdiction of incorporation or organization)

 (I.R.S. Employer Identification No.)

 1609 W Valley Blvd, Unit 338A, Alhambra, CA

 91803

 (Address of principal executive offices)

 (Zip Code)

 Registrant's
telephone number, including area code: (888) 988-1333

 Securities
registered pursuant to Section 12(b) of the Act: None

 Securities
registered pursuant to Section 12(g) of the Act: Common Stock, no par value

by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

 Yes
 No

by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.

 Yes
 No

 Note
 – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange
Act from their obligations under those Sections.

by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

 Yes
 No

by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).

 Yes
 No

by check mark if disclosure of delinquent filers pursuant to item 405 of Regulation S-K (§229.405 of this chapter) is not contained
herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated
by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

 Yes
 No

by check mark whether the registrant is large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See definition of "large accelerated filer," accelerated filer" "smaller reporting
company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

 Large accelerated filer
 Accelerated filer

 Non-accelerated filer
 Smaller Reporting Company

 Emerging growth company

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

 Yes
 No

the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date. The number
of shares outstanding of the registrant's common stock as of September 30, 2024 was 21,188,988,326.

 FORM 10-K

 For the Year Ended June 30, 2024

 Page

 Item 1.

 Business

 Item 1A.

 Risk Factors

 Item 1B.

 Unresolved Staff Comments

 Item 1C

 Cybersecurity

 Item 2.

 Properties

 Item 3.

 Legal Proceedings

 Item 4.

 Mine Safety Disclosures

 Item 5.

 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Item 6.

 Selected Financial Data

 Item 7

 Management's Discussion and Analysis of Financial Condition and Results of Operations

 Item 7A.

 Quantitative and Qualitative Disclosures about Market Risk

 Item 8.

 Financial Statements and Supplementary Data

 Item 9.

 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 Item 9A.

 Controls and Procedures

 Item 9B.

 Other Information

 Item 9C.

 Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

 Item 10.

 Directors, Executive Officers and Corporate Governance

 Item 11.

 Executive Compensation

 Item 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item 13.

 Certain Relationships and Related Transactions, and Director Independence

 Item 14.

 Principal Accounting Fees and Services

 Item 15.

 Exhibits, Financial Statement Schedules

 Signatures

 In
this annual report the words "we," "us," "our," and the "Company" refer to America Great
Health and subsidiaries.

 FORWARD
LOOKING STATEMENTS

 When
used in this report, the words "may," "will," "expect," "anticipate," "continue,"
"estimate," "project," "intend," and similar expressions are intended to identify forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding
events, conditions, and financial trends that may affect the Company's future plans of operations, business strategy, operating
results, and financial position. Persons reviewing this report are cautioned that any forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties and that actual results may differ materially from those included within
the forward-looking statements as a result of various factors.

 Statements
made in this Form 10-K that are not historical or current facts are "forward-looking statements" made pursuant to the safe
harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date
made. Any forward-looking statements represent our best judgment as to what may occur in the future. These forward-looking statements
include our plans and objectives for our future growth, including plans and objectives related to the consummation of acquisitions and
future private and public issuances of our equity and debt securities. The forward-looking statements included herein are based on current
expectations that involve numerous risks and uncertainties. Assumptions relating to the foregoing involve judgments with respect to,
among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible
to predict accurately and many of which are beyond our control. Although we believe that the assumptions underlying the forward-looking
statements are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking
statements included in this Form 10-K will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking
statements included herein, you should not regard the inclusion of such information as our representation or the representation of any
other person that we will achieve our objectives and plans. We disclaim any obligation subsequently to revise any forward-looking statements
to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

 PART
I

 ITEM
1. BUSINESS

 Historical
Development

Great Health, formerly Crown Marketing, is a Wyoming corporation (the "Company"). A change of control of the Company was
completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control
was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In
connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary
in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company's operations are determined
and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations
up to January 1, 2017 as discontinued operations.

 On
March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate
name from Crown Marketing to America Great Health.

 On
March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California.

 On
June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary
is mainly engaged in mergers and acquisitions, investments and financings, and marketing of medical equipment and health products in
China.

 On
June 30, 2020, the Company and Purecell Group ("Purecell"), a leading anti-aging medical institution in Australia, entered
into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell. On April 6, 2021, the Company issued
510,000,000 shares of common stock to Purecell's nominated trustee. Upon completion of the acquisition transaction, Purecell shall
remain autonomous in its day-to-day operations, including recruiting and retaining management team members. Because the Company does
not have significant control over Purecell, the acquisition is accounted for as an equity investment. This transaction was completed
in May 2021.

 On
December 7, 2020, the Company's wholly owned Californian subsidiary, America Great Health, entered into a Cooperation Agreement
with Brilliant Healthcare Limited ("Brilliant") pursuant to which the parties will establish a joint venture in China (the
"JV Company") for the purpose of promoting and developing stem cell related product's R&D, production, sales, raw
material procurement, mergers and acquisitions, and consulting services. After the formation of the JV company is completed, the Company
shall invest US$4.2 million in the JV Company within the next 24 months for a 60% equity ownership in the JV Company. Brilliant shall
transfer its patented technology to the JV Company as its capital contribution, to account for a 40% equity interest in the JV Company.
In June 2021, the JV Company was established in Hainan, China as "Sijinsai (Hainan) Biological Tech Ltd." On July 9, 2021,
the Company paid its first investment of $50,000.

 On
May 18, 2021, the Company and David Tsai ("Dr. Tsai"), a pioneer in anti-cancer peptide research and invention in the United
States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company theories, technologies, methods, sources
of raw materials, processing and production techniques, quality standards, quality control methods and other information and details
related to his anti-cancer protein peptides, oral insulin and activation technology. Dr. Tsai shall also be responsible for the whole
process of technology and product production, application and implementation, as well as professional technical support, consultation
and cooperation in the process of product verification, publicity, promotion and sales. Currently, several patents are in the application
process, and several products are in the process of getting ready for production.

 On
September 3, 2021, the Company entered into an Assets Acquisition Agreement with Wang's Property Investment & Management
LLC to purchase 53 units in 19 real estate properties appraised at $7,626,286.37 for a purchase price of $7,000,000, The purchase
price shall be paid as follows (i) 1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the
remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. On
September 9, 2021, the Company entered into a Supplemental Assets Acquisition Agreement with Wang's Property Investment &
Management LLC to amend and clarify that (i) it was purchasing 19 real estate properties which includes 53 units appraised at
$7,626,286.37 for a purchase price of $7,000,000 and (ii) that it will waive and not conduct due diligence in order for the
transaction to proceed. The acquisition had been ceased by both sides without any liabilities and obligations to the Company and
Wang's Property Investment & Management LLC.

 On
November 4, 2021, the Company set up a 100% owned subsidiary Nutrature Health LLC. On November 11, 2021, America Great Health (the "Company")
entered into an Advisory Committee Member Consulting Agreement with Dr. Kevin Buckman MD ("Consultant"). Pursuant to the
Agreement, Consultant is to provide advisory services, as a member to the Advisory Committee to the Board of Directors of the Company,
including without limitation, assisting GOF Biotechnologies Inc. in its new drug approval process for oral insulin and Amylase X. Consultant
shall be compensated with a warrant to purchase 500,000 shares of the Company at $0.01 per share within 24 months and a warrant at each
of the following stages: IND application, Phase I clinical trials, Phase II clinical trials, Phase III clinical trials and the sale of
GOF Biotechnologies Inc. the license of oral insulin and Amylase X at Phase I or Phase II clinical trials stages. This Agreement shall
be for an initial one year term and shall renew automatically for successive one-year terms up to a maximum of three (3) years unless
terminated by either party pursuant to the Agreement. The Company issued 500,000 shares to Dr. Kevin Buckman MD on April 20, 2022.

 On
November 15, 2021, the Company set up a 100% owned subsidiary GOF Biotechnologies Inc. GOF is 75% majority owned (60,000,000 shares of
common stock) by the Company and the remaining 25% of its issued and outstanding shares (20,000,000 shares of common stock) are held
by Men Hwei, Tsai. On December 31, 2021, the Company entered into a Supplementary Agreement with Zhigong Lin to amend his prior employment
agreement with the Company dated August 31, 2021. The Supplement Agreements provides, inter alia, that Zhigong Lin would be appointed
Chief Executive Officer of GOF. The employment agreement and the supplement agreement had both been terminated without any liabilities
and obligation to the Company and Zhigong Lin.

 On
February 4, 2021, the Company set up a 100% owned subsidiary International Institute of Great Health, Inc. (IIGH) under the laws of the
State of California. The Company wholly owned research institute will bring together doctors and professor-level experts from different
countries and regions in the world. The research fields involve biomedicine, clinical medicine, health management, information technology,
data analysis, software development, artificial intelligence, industrial planning, financial investment, etc.

 Our
Business

 Prior
to the change in control on January 19, 2017, the Company sold consumer products. It acquired electronic products from manufacturers
and then sold them directly to consumers so as to be more competitive in price. As of December 31, 2016, the Company ceased operations
in this line of business.

 The
Company under the new management has focused its business in the health industry. With the asset acquisition from Wang's Property
Investment & Management LLC, the Company attempted diversify its business into property investment and management. By the early May
2022, the acquisition had been ceased by both sides.

 Apart
from the acquisition of Purecell and the setting up of the JV Company, the Company is planning to make additional acquisitions. We have
approached several health related companies in Asia Pacific and met the management of potential acquisition targets. Rapid economic advances
in Asia Pacific in the last 20 years have greatly improved the living standards in Asia Pacific. This in turn brings demand in healthcare
products and services. The Company feels strongly that despite the challenges of cross border business, it might be able to acquire some
good growth companies and bring good values to our stockholders.

 Our
mission is to invest in innovative technologies integrated with business development in the healthcare ecosystem.

 We
are focused on protein and peptide small molecular drugs research and development, diagnostic and medical devices with AI cloud computing,
cell therapy, and re-generational medicine and supplements manufacturing and sales.

 Employees
and Outside Services

 The
company has five (5) full-time employees as of report date. Remaining administrative (non-policy making) officers and consultants and
technical personnel such as marketing specialists are being compensated as independent contractors. We pay these persons on a contract
basis as required.

 ITEM
1A. RISK FACTORS

 This
item is inapplicable because we are a "smaller reporting company" as defined in Exchange Act Rule 12b-2.

 ITEM
1B. UNRESOLVED STAFF COMMENTS

 This
item is inapplicable because we are a "smaller reporting company" as defined in Exchange Act Rule 12b-2.

 ITEM 1C. CYBERSECURITY

 As a publicly traded company, the
Company recognized the critical importance of effective cybersecurity risk management to safeguard our operations, protect sensitive information
and ensure the trust of the Company's customers and stakeholders.

 Risk Management & Strategy

 The Company is in the process of maintaining a robust cybersecurity risk
management program designed to assess, identify and manage material risks from cybersecurity threats, which encompasses these areas: risk
assessment, incident detection and response, third-party risk, governance, board of directors' oversight, and management's
role in managing cybersecurity risk.

 ITEM
2. PROPERTIES

 The
Company currently is leasing an office building property in Los Angeles County California. The Company has a month-to-month leases agreement
with GKT, Alhambra, LP after the previous lease term of the office space expired on November 30, 2023. The current monthly rent including
monthly management fee is $4,939.17.

 The
Company has entered into an operating lease agreement with SoCal Industrial LLC, Irwindale. The lease term of the office space is from
June 1, 2024 to May 31, 2026, after the prior lease expired on May 31, 2024. The current monthly rent including monthly management fee
is $1,940.40.

 ITEM
3. LEGAL PROCEEDINGS

 No
legal proceedings are threatened or pending against us or any of our officers or directors. Further, none of our officers, directors
or affiliates are parties against us or have any material interests in actions that are averse to the Company's interests.

 ITEM
4. MINE SAFETY DISCLOSURES

 Not
applicable.

 PART
II

 ITEM
5. MARKET FOR REGISTRANT ' S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 Market
Information

 Our
common stock is currently listed on the OTC Bulletin Board under the symbol "AAGH". There has been limited trading of the
common stock from December 2, 2013 (Inception) through June 30, 2024. The last sale price of our common stock on June 30, 2024, was 0.0028
per share.

 The
following table sets forth the high and low transaction price for each quarter within the fiscal years ended June 30, 2024 and 2023,
as provided by the NASDAQ Stock Markets, Inc. The information reflects prices between dealers, and does not include retail markup, markdown,
or commissions, and may not represent actual transactions.

 Fiscal Year Ended

 Bid Prices

 Period

 High

 Low

 2024

 First Quarter

 $
 0.0079

 $
 0.0002

 Second Quarter

 $
 0.0210

 $
 0.0024

 Third Quarter

 $
 0.0210

 $
 0.0011

 Fourth Quarter

 $
 0.0040

 $
 0.0001

 2023

 First Quarter

 $
 0.1850

 $
 0.0300

 Second Quarter

 $
 0.2299

 $
 0.1010

 Third Quarter

 $
 0.1649

 $
 0.0010

 Fourth Quarter

 $
 0.0800

 $
 0.0002

 Our
shares are subject to Section 15(g) and Rule 15g-9 of the Securities and Exchange Act, commonly referred to as the "penny stock"
rule. The rule defines penny stock to be any equity security that has a market price less than $5.00 per share, subject to certain exceptions.
The rule provides that any equity security is considered to be a penny stock unless that security is:

 -
 registered
 and traded on a national securities exchange meeting specified criteria set by the SEC;

 -
 issued
 by a registered investment company;

 -
 excluded
 from the definition on the basis of price (at least $5.00 per share) or the issuer's
 net tangible assets.

 Trading
in the penny stocks is subject to additional sales practice requirements on broker-dealers who sell penny stocks to persons other than
established customers and accredited investors. Accredited investors, in general, include certain institutional investors and individuals
with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse.

 For
transactions covered by these rules, broker-dealers must make a special suitability determination for the purchase of our securities
and must have received the purchaser's written consent to the transaction prior to the purchase. Additionally, for any transaction
involving a penny stock, the rules require the delivery, prior to the first transaction of a risk disclosure document relating to the
penny stock. A broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative,
and current quotations for the security. Finally, monthly statements must be sent to the purchaser disclosing recent price information
for the penny stocks. Consequently, these rules may restrict the ability of broker-dealers to trade or maintain a market in our common
stock and may affect the ability of shareholders to sell their shares.

 Holders

 As
of June 30, 2024, there were approximately 871 shareholders of record holding 21,188,988,326 shares of common stock. The holders of common
stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Holders of the common
stock have no preemptive rights and no right to convert their common stock into any other securities. There is no redemption or sinking
fund provisions applicable to the common stock.

 Dividends

 The
Company has not paid any dividends on its common stock. The Company current intends to retain any earnings for use in its business, and
therefore does not anticipate paying cash dividends in the foreseeable future.

 Securities
Authorized Under Equity Compensation Plans

 The
following table lists the securities authorized for issuance under any equity compensation plans approved by our shareholders and any
equity compensation plans not approved by our shareholders as of June 30, 2024. This chart also includes individual compensation agreements.

 EQUITY
COMPENSATION PLAN INFORMATION

 Plan category

 Number of securities

to be issued

upon exercise

of outstanding options,

warrants and rights

(a)

 Weighted-average

exercise price of

outstanding options,

warrants and rights

(b)

 Number of securities

 remaining available for

 future issuance under

 equity compensation

 plans (excluding

 securities reflected

 in column (a))

 (c)

 Equity compensation plans approved by security holders

 $
 0.00

 Equity compensation plans not approved by security holders

 $
 0.00

 Total

 $
 0.00

 Company
repurchases of common stock during the year ended June 30, 2024

 None

 Performance
Graphic

 This
item is not required to provide a performance graph since it is a "smaller reporting company" as defined in Exchange Act
Regulation S-K Rule 10(f).

 Share
issuances in year ended June 30, 2024

 All
share issuances have been previously reported.

 ITEM
6. [Reserved]

 ITEM
7. MANAGEMENT ' S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

 Forward
Looking Statement Notice

 This
Current Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws. These include statements
about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as "anticipate,"
"expect," "intend," "plan," "will," "we believe," "believes,"
"management believes" and similar language. Except for the historical information contained herein, the matters discussed
in this "Management's Discussion and Analysis of Financial Condition and Results of Operations," and elsewhere in this
report are forward-looking statements that involve risks and uncertainties. The factors listed in the section captioned "Risk Factors,"
as well as any cautionary language in this report; provide examples of risks, uncertainties and events that may cause our actual results
to differ materially from those projected. Except as may be required by law, we undertake no obligation to update any forward-looking
statement to reflect events after the date of this Form 10-K.

 Overview
of Business

 Our
mission is to invest in innovative technologies, integrated with business development in the healthcare ecosystem.

 We
are focused on protein and peptide small molecular drugs research and development, diagnostic and medical devices with AI cloud computing,
cell therapy and regenerational medicine and supplements manufacturing and sales.

 On
September 3, 2021, the Company entered into an Assets Acquisition Agreement with Wang's Property Investment & Management LLC
to purchase 53 units in 19 real estate properties appraised at $7,626, 286.37 for a purchase price of $7,000,000, The purchase price
shall be paid as follows: (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder
by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. On September 9, 2021,
the Company entered into a Supplemental Assets Acquisition Agreement with Wang's Property Investment & Management LLC to amend
and clarify that (i) it was purchasing 19 real estate properties which includes 53 units appraised at $7,626,286.37 for a purchase price
of $7,000,000 and (ii) that it will waive and not conduct due diligence in order for the transaction to proceed. The acquisition has
not been consummated. With the asset acquisition from Wang's Property Investment & Management LLC, the Company will diversify
its business into property investment and management. By the end of May 2022, the Company ceased the acquisition of Wang's Property
Investment & Management LLC.

 Results
of Operations

 Results
of Operations for the year ended June 30, 2024 compared to the year ended June 30, 2023.

 Sales
amounted to $294,670 and $204,308 for the years ended June 30, 2024 and 2023, respectively.

 Cost
of goods sold amounted to $124,920 and $35,720 for the years ended June 30, 2024 and 2023, respectively.

 Gross
profit amounted to $169,750 and $168,588 for the years ended June 30, 2024 and 2023, respectively.

 Operating
expenses for the year ended June 30, 2024 and 2023 were $952,450 and $661,232, respectively. The increase was mainly due
to increased payroll expenses, travel expenses, advertising, and professional expenses.

 Our
net loss for the year ended June 30, 2024 and 2023 was $1,226,362 and $777,340, respectively. The increase in
net loss was mainly due to the increased cost of goods sold and operating expenses.

 Liquidity
and Capital Resources

 Liquidity
is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate
on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable
and accounts payable and capital expenditure.

 The
accompanying Consolidated Financial Statements ("CFS") were prepared on a going concern basis, which contemplates the
realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the
accompanying CFS, the Company has incurred recurring net losses. For the year ended June 30, 2024 the Company recorded a net loss of
$1,226,362, used cash to fund operating activities of $615,627 and at June 30, 2024, had a shareholders' deficit of
$5,311,599. For the year ended June 30, 2023, the Company recorded a net loss of $777,340, used cash to fund operating activities of
$389,809, and on June 30, 2023, had a shareholders' deficit of $4,370,836. These factors create substantial doubt
about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might
be necessary if the Company is unable to continue as a going concern.

 The
Company is raising additional capital to achieve profitable operations.

 Our
cash needs for the year ended June 30, 2024 were primarily met by loans and advances from our current majority shareholder. As of June
30, 2024, we had a cash balance of $54,943. Our future majority shareholders will need to provide all of our working capital going forward.

 Primarily
as a result of our recurring losses and our lack of liquidity, we received a report from our independent registered public accounting
firm for our financial statements for the year ended June 30, 2024 that includes an explanatory paragraph describing the uncertainty
as to our ability to continue as a going concern.

 Financial
Position

 As
of June 30, 2024, we had $54,943 in cash, a working capital deficit of $3,367,989 and an accumulated deficit of $10,248,681.

 Critical
Accounting Policies and Estimates

 Estimates

 The
preparation of these consolidated financial statements ("CFS") in accordance with accounting principles generally accepted
in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the consolidated financial statements
and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such
differences may be material to the financial statements. The more significant estimates and assumptions by management include among others,
the fair value of shares of common stock issued for services. The current economic environment has increased the degree of uncertainty
inherent in these estimates and assumptions.

 Revenues

 Revenue
from sale of goods under Topic 606, Revenue from Contracts with Customers, is recognized in a manner that reasonably reflects the delivery
of the Company's products and services to customers in return for expected consideration and includes the following elements:

 executed
 contract(s) with customers that the Company believes is legally enforceable;

 identification
 of performance obligation in the respective contract;

 determination
 of the transaction price for each performance obligation in the respective contract;

 allocation
 of the transaction price to each performance obligation; and

 recognition
 of revenue only when the Company satisfies each performance obligation.

 Inventories

 Inventories
are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net
realizable value are made, if required, for estimated excess, obsolescence, or impaired balances.

 Fair
Value Measurements

 Fair
value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance
to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price
that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which
prioritizes the inputs used in measuring fair value into three broad levels as follows:

 Level 1—Quoted prices in active markets for identical assets or liabilities.

 Level
2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

 Level
3—Unobservable inputs based on the Company's assumptions.

 The
Company is required to use observable market data if available without undue cost and effort.

 The
Company's financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate
their fair value due to the short-term nature.

 Basic
and Diluted Loss Per Share

 Basic
and diluted loss per share is computed based on the weighted-average common shares and common share equivalents outstanding during the
period. Common share equivalents consist of stock options, restricted stock, warrants, convertible related party notes payable, and convertible
preferred stock. Common share equivalents were excluded from the computation of diluted earnings per share for the year ended June 30,
2024 and 2024, because their effect was anti-dilutive.

 Weighted
average shares of common stock outstanding used in the calculation of basic and diluted earnings per share were as follows:

 June 30

 2024

 2023

 Net loss per share, basic and diluted

 $
 (0.00
)

 $
 (0.00
)

 Weighted average shares outstanding:

 Total weighted average common shares outstanding – basic and diluted

 21,123,253,567

 21,093,402,806

 Antidilutive securities not included:

 Stock options

 -

 -

 Stock options arising from convertible note payable and accrued interest

 -

 -

 Restricted stock grants

 18,127,152,400

 17,690,675,472

 Convertible preferred stock

 -

 -

 Total

 18,127,152,400

 17,690,675,472

 Income
Taxes

 Income
tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences
of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded
to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against
its deferred tax assets as of June 30, 2024 and 2023.

 The
Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The
first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more
likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The
Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt)
of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.

 Recent
Accounting Pronouncements

 See
Footnote 2 of the financial statements for a discussion of recently issued accounting standards.

 Contractual
Obligations and Off-Balance Sheet Arrangements

 We
do not have any contractual obligations or off-balance sheet arrangements.

 ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 We
are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information
under this item.

 ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 Our
financial statements appear beginning on page F-1 in this Form 10-K.

 ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 None.

 ITEM
9A. CONTROLS AND PROCEDURES

 Evaluation
of Disclosure Controls and Procedures

 Based
upon an evaluation of the effectiveness of our disclosure controls and procedures performed by our Chief Executive Officer as of the
end of the period covered by this report, our Chief Executive Officer concluded that our disclosure controls and procedures have not
been effective as a result of a weakness in the design of internal control over financial reporting identified below.

 As
used herein, "disclosure controls and procedures" mean controls and other procedures of our company that are designed to
ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls
and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us
in the reports that we file or submit under the Securities Exchange Act is accumulated and communicated to our management, including
our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions
regarding required disclosure.

 Management ' s
Annual Report on Internal Control over Financial Reporting

 Management
is responsible for establishing and maintaining adequate internal control over financial reporting ("ICFR"), as such term
is defined in Exchange Act Rule 13a-15(f) under the Securities Exchange Act of 1934. Our Chief Executive Officer/Chief Accounting Officer
conducted an evaluation of the effectiveness of our ICFR based on the framework in Internal Control-Integrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway Commission ("COSO 2013"). Based on management's evaluation under
the framework, management has concluded that our ICFR was not effective as of June 30, 2024.

 We
identified material weaknesses in our ICFR primarily attributable to (i) lack of segregation of incompatible duties; and (ii) insufficient
Board of Directors representation. These weaknesses are due to our inadequate staffing during the period covered by this report and our
lack of working capital to hire additional staff. Management has retained an outside, independent financial consultant to record and
review all financial data, as well as prepare our financial reports, in order to mitigate this weakness. Although management will periodically
re-evaluate this situation, at this point it considers that the risk associated with such lack of segregation of duties and the potential
benefits of adding employees to segregate such duties are not cost justified. We intend to hire additional accounting personnel to assist
with financial reporting as soon as our finances will allow.

 This
annual report does not include an attestation report of our registered public accounting firm regarding ICFR. Management's report
was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission
that permit us to provide only management's report in this annual report.

 ITEM
9B. OTHER INFORMATION

 None.

 ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 None.

 PART
III

 ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 Set
forth below are the names of our directors, executive officers and significant employees of our company as of the date of this Form 10-K,
their ages, all positions and offices that they hold with us, the periods during which they have served as such, and their business experience
during at least the last five years.

 Name

 Position with
 the Company

 Age

 Period

 Mike Wang

 Chairman of the
 Board of Directors, President, Chief Executive Officer

 2017 – Present

 Rex Chang

 2018 – Present

 Aihua Guo

 2020 – Present

 Peter Britton

 2020 – Present

 Jiaxin Xue

 2018 – Present

 Quinn Chen

 Chief Financial
 Officer

 2022 – Present

 Name

 Position
 with the Company and Principal Occupations

 Mike
Wang

 Chairman of the Board of
 Directors, President, Chief Executive Officer and Chief Financial Officer since 2017. Mr. Wang has served as the Chief Financial
 Officer of our company since 2017. He has been working in the health supplements business for about 20 years. From 2012 to present,
 he worked as the vice-president of the American Nutrition and Health Association. From 2013 to present, he worked as the president
 of the Health & Beauty Group Inc. From 2016 to present, he worked as our President, Chief Executive Officer and Chief Financial
 Officer.

 Rex
Chang

Mr. Rex Chang is an experienced GPA Consultant and an international trade specialist. He started in manufacturing facilities, well-trained
in commercial and industrial, import-export, QC/QA, marketing development and government procurement. Mr. Chang served as Chief Executive
Officer in U. S. Asia Chamber of Commerce, and Chief Executive Officer- Asian Marketing in U.S. Foods International. He also served as
Chief Executive Officer of New Cathay International Development Corp. Mr. Chang is consultant to the Center for International Trade Development
and Taiwan Trade Center.

 Aihua
Guo

Ms. Aihua Guo is an entrepreneur and founder of Hong Kong-based Brilliant Health Co., Ltd., which she founded in 2018. She has been the
standing editor of Chinese Journals of Tissue Engineering and Aesthetic Plastic Surgery since 2018. She has also been the visiting professor
of Galway Institute of Regenerative Medicine in Ireland and CEO of Pure Athesthetic Co., Ltd. of Hong Kong since 2017. From 2016 to 2018,
Ms. Guo served as the business director of China Regenerative Medicine International Co., Ltd. She has been the members of British Blood
Transfusion Association, Illouz Foundation France and China Plastic Surgery Association since 2015. Ms. Guo obtained her MD of Plastic
Surgery in 2012 and PhD of Immunology of Transplantation and Ophthalmology in 2007.

 Peter
Britton

 Director.
 Mr. Peter Britton is the founder and board chairman of Purecell Group, co-inventor of UCF (Umbilical Cord Factors) global patent,
 and international expert on translational cellular regenerative medicine. He is the director and chief scientist of Purcell in the
 development, commercialization and multiple medical applications of Purecell patented anti-aging products and technologies including
 UCF, Exosome, NAD+, SKQ1 and Liposome. He currently serves as the chief scientist and director of the joint-venture between Purecell
 and BoaoYiling Life Care Center in China, which leads the world-first officially-approved medical application and commercialization
 of UCF technology in the field of degenerative joint disease. He is also the founder of Hong Kong-based N Cell, a leading provider
 of proteomic analysis for Asian market since 2016, and has been the founding member of the Sino-Australian Stem Cell Centre of
 Excellence with Peking University since 2015. Mr. Peter Britton graduated with a bachelor's degree from the University of
 Sydney, and obtained post graduate work at the University of Bern in Switzerland.

 Jiaxin Xue

 Director.
 Mr. Jiaxin Xue is graduate of Henan Medical University. He also obtain Doctor degree in Natural Medicine from American Naturopathic
 University, Master's degree in Social Medicine and Health Management from Peking Union Medical College, Mr. Xue obtained PhD
 degree in Social Economics, School of Philosophy and Sociology from Beijing Normal University. He is an experienced specialist
 involves comprehensive fields such as medical treatment, medicine, health, rehabilitation, and elderly care. From 2007 to 2008, Mr.
 Xue was the Deputy Director of the Chinese Red Cross Rescue Training Department, Vice President of the Business Development
 Department of Haihong Pharmaceutical Holdings; in 2009 Mr. Xue founded Mai Dingsheng International Medical Investment Service
 Agency. From 2014 to the present, Mr. Xue is the Deputy Dean of the International College of Natural Therapy, Executive Vice
 President of the Zhongguancun Industry Integration and Transformation Promotion Association and Chairman of the International
 Medical Care Industry Committee, Deputy Director of the Chronic Disease Prevention Fund Management Committee of the China Medical
 and Health Development Foundation, Chinese Nationality Deputy Director of the Internet + Medical Work Committee of the Health
 Association, Deputy Director of the Clinical Medicine Center of the Research Institute of the National Health
 Commission.

 Quinn Chen

 CFO.
Mr. Quinn Chen has more than two decades of practice experience in public and private accounting where he specialized in both private
and public company financial audits, oversight over financial reporting, cash management, tax compliance, and mergers and acquisitions.
From October 2018 through present date, Mr. Chen was the Chief Financial Officer of NuOrganic Cosmetics. From September 2014 –July
2019, he was a financial controller at Gardiner & Theobald, an independent global consultancy to the construction and property industry.
At the same time, he served as the chief tax consultant of real estate investments at 42nd Street Realty, a well- known Times Square
Realty Company of New York City, and provided consulting service in asset management and tax planning of trusts and estates to high-profile.
Prior to that, Mr. Chen spent about ten years as an auditor and tax accountant with several public accounting firms in the New York City
metropolitan area. Mr. Chen holds a Master of Business Administration from Baruch College, Zicklin School of Business.

 All
our directors hold office until the next annual meeting of our shareholders or until their successors have been elected and qualified.
The executive officers of our company are appointed by our board of directors and hold office until their death, resignation, or removal
from office.

 Family
Relationships

 There
is no family relationship among any of our officers or directors.

 Code
of Ethics

 The
Company has not adopted a code of ethics which applies to the chief executive officer, or principal financial and accounting officer,
because of our current low level of operations as a public entity. The Company intends to adopt a code of ethics in the near future.

 Audit
Committee Financial Expert

 The
Company does not have either an Audit Committee or a financial expert on the BOD. The BOD believes that obtaining the services of an
audit committee financial expert is not economically rational at this time in light of the costs associated with identifying and retaining
an individual who would qualify as an audit committee financial expert, the limited scope of our operations and the relative simplicity
of our financial statements and accounting procedures.

 Section
16(a) Beneficial Ownership Reporting Compliance

 Section
16(a) of the Exchange Act requires our executive officers and directors and persons who own more than 10% of a registered class of our
equity securities to file with the SEC initial statements of beneficial ownership, reports of changes in ownership and annual reports
concerning their ownership of our common stock and other equity securities, on Form 3, 4 and 5 respectively. Executive officers, directors
and greater than 10% shareholders are required by the SEC regulations to furnish our Company with copies of all Section 16(a) reports
they file.

 Based
solely on our review of the copies of such reports received by us and on written representations by our officers and directors regarding
their compliance with the applicable reporting requirements under Section 16(a) of the Exchange Act, On the fiscal year ended June 30,
2024, two new board members, Mr. Peter Britton, Ms. Aihua Guo did not file Forms 3.

 ITEM
11. EXECUTIVE COMPENSATION

 Executive
Officers and Directors

 The
following tables set forth certain information about compensation paid, earned or accrued for services by (i) the Company's Chief
Executive Officer and Chief Financial Officer in the years ended June 30, 2024 and 2023 ("Named Executive Officers"):

 Non-Equity

 Incentive

 Nonqualified

 Name and

 Stock

 Option

 Plan

 Deferred

 All Other

 Salary

 Bonus

 Awards

 Awards

 Compensation

 Compensation

 Compensation

 Total

 Position

 Year

 ($)

 ($)

 ($)

 ($)

 ($)

 ($)

 ($)

 ($)

 Mike Q. Wang

 President/CEO

 2024

 $

 54,000

 -

 -

 -

 -

 -

 -

 $

 54,000

 2023

 $

 43,800

 -

 -

 -

 -

 -

 -

 $

 43,800

 Quinn Chen

 CFO

 2024

 $

 11,077

 -

 -

 -

 -

 -

 -

 $

 11,077

 2023

 $

 8,308

 -

 -

 -

 -

 -

 -

 $

 8,308

 Employment
Contracts

 We
currently do not have any written employment agreements with our executive officers.

Compensation

 None
of our directors was compensated for their services to the board other than Ms. Aihua Guo was paid $6,199 and $- respectively for the
years ended June 30, 2024 and 2023.

Qualifications

 Directors
are responsible for overseeing the Company's business consistent with their fiduciary duty to the shareholders. This significant
responsibility requires highly skilled individuals with various qualities, attributes and professional experience. Our BOD believes that
there are general requirements for service on the BOD that are applicable to directors and that there are other skills and experience
that should be represented on the BOD as a whole but not necessarily by each director. The BOD considers the qualifications of director
and director candidates individually and in the broader context of the BOD's overall composition and the Company's current
and future needs.

 Qualifications,
Attributes, Skills and Experience to be Represented on the Board as a Whole

 The
BOD has identified particular qualifications, attributes, skills and experience that are important to be represented on the board as
a whole, in light of the Company's current needs and its business priorities. The BOD believes that it should include some directors
with a high level of financial literacy and some directors who possess relevant business experience as a Chief Executive Officer or a
President or like position. Marketing is the core focus of our business, and the Company seeks to develop and deploy the world's
most innovative and effective marketing and technology. Therefore, the Board believes that marketing and technology experience should
be represented on the BOD. Since the Company is involved in the healthcare business, the Company's business also requires compliance
with a variety of regulatory requirements and relationships with various governmental entities. Therefore, the BOD believes that governmental,
political, or diplomatic expertise should be represented on the Board.

 Set
forth below are a chart and a narrative disclosure that summarize the specific qualifications, attributes, skills and experiences described
above. An "X" in the chart below indicates that the item is a specific reason that the director has been nominated to serve
on the Company's Board. The lack of an " X " for a particular qualification does not mean that the director
does not possess that qualification or skill. Rather, an "X" indicates a specific area of focus or expertise of a director
on which the BOD currently relies.

 High level of financial literacy

 Mike
 Q. Wang

 Quinn
 Chen

 X

 Extensive knowledge of the Company's business

 X

 X

 Marketing/Marketing related technology experience

 X

 Relevant Chief Executive/President or like experience

 X

 X

 Corporate Governance expertise

 X

 X

 Directors
or Executive Officers involved in Bankruptcy or Criminal Proceedings

 To
our knowledge, during the last ten years, none of our directors and executive officers (including those of our subsidiaries), has:

 Had
 a bankruptcy petition filed by or against any business of which such person was a general
 partner or executive officer either at the time of the bankruptcy or within two years prior
 to that time.

 Been
 convicted in a criminal proceeding or been subject to a pending criminal proceeding, excluding
 traffic violations and other minor offenses.

 Been
 subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
 of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending
 or otherwise limiting his involvement in any type of business, securities or banking activities.

 Been
 found by a court of competent jurisdiction (in a civil action), the SEC, or the Commodities
 Futures Trading Commission to have violated a federal or state securities or commodities
 law, and the judgment has not been reversed, suspended or vacated.

 Been
 the subject to, or a party to, any sanction or order, not subsequently reversed, suspended
 or vacated, of any self-regulatory organization, any registered entity, or any equivalent
 exchange, association, entity or organization that has disciplinary authority over its members
 or persons associated with a member.

 Board
Meetings

 The
BOD held one meeting during FY 2024.

 Material
Changes to the Procedures by which Security Holders May Recommend Nominees to the Board of Directors

 There
have been no material changes to the procedures by which security holders may recommend nominees to the BOD.

 Board
Leadership Structure and Role in Risk Oversight

 Mr.
Mike Q. Wang is our Chairman, Chief Executive Officer. As a main officer and director, Mr. Wang, by default, serves as our business and
industry leader most capable of identifying strategic priorities and executing our business strategy. In addition, having a single leader
eliminates the potential for confusion and provides clear leadership for the Company. We believe that this leadership structure has served
the Company well. The Board's role in the risk oversight of the Company includes, among other things:

 appointing,
 retaining and overseeing the work of the independent auditors, including resolving disagreements
 between the management and the independent auditors relating to financial reporting;

 approving
 all auditing and non-auditing services permitted to be performed by the independent auditors;

 reviewing
 annually the independence and quality control procedures of the independent auditors;

 reviewing
 and approving all proposed related party transactions;

 discussing
 the annual audited financial statements with the management; and

 meeting
 separately with the independent auditors to discuss critical accounting policies, management
 letters, recommendations on internal controls, the auditor's engagement letter and
 independence letter and other material written communications between the independent auditors
 and the management.

 Our
BOD is responsible for approving all related party transactions. We have not adopted written policies and procedures specifically for
related person transactions.

 ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 Beneficial
Ownership

 The
following table sets forth, as of the date of this report the outstanding common stock of the Company owned of record or beneficially
by each person who owned of record, or was known by the Company to own beneficially, more than 5% of the Company's 21,107,081,148
shares of common stock issued and outstanding, and the name and shareholdings of each director and all of the executive officers and
directors as a group.

 Unless
otherwise indicated in the footnotes to the following table, each person named in the table has sole voting and power and that person's
address is c/o 1609 W Valley Blvd., Unit 338A, Alhambra, CA 91803:

 CERTAIN
BENEFICIAL OWNERS

 Amount and

 nature of

 beneficial

 Percent

 Name

 Office

 owner (1)

 of class

 Mike Q. Wang

 Chief Executive Officer, Director

 862,132,441

 4.07
 %

 Rex Chang

 202,500,000

 0.96
 %

 Aihua Guo

 311,797,747

 1.47
 %

 Peter Britton

 --

 --

 Jianxin Xue

 627,000,000

 2.96
 %

 All officer and directors as a group (5 person)

 N/A

 2,188,988,326

 9.46
 %

 (1)
 Except
 as otherwise noted, shares are owned beneficially and of record, and such record shareholder
 has sole voting, investment, and dispositive power.

 ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 During
the year ended June 30, 2024, the Company's current majority shareholder advanced $969,868 to the Company as working
capital and the Company repaid $276,596 to the shareholder. As of June 30, 2024 and 2023, the Company owed its current majority shareholder
and other related $1,110,196 and $425,142 respectively. The advances are non-interest bearing and are due on demand.

Independence

 Currently,
the Company does not have any independent directors. Since the Company's common stock is not currently listed on a national securities
exchange, we have used the definition of "independence" of The NASDAQ Stock Market to make this determination.

 Under
NASDAQ Listing Rule 5605(a)(2), an "independent director" is a "person other than an officer or employee of the company
or any other individual having a relationship which, in the opinion of the company's board of directors, would interfere with the
exercise of independent judgment in carrying out the responsibilities of a director."

 We
do not currently have a separately designated audit, nominating or compensation committee. However, we do intend to comply with the independent
director and committee composition requirements in the future.

 ITEM
14. PRINCIPAL ACCOUNTING FEES AND SERVICES

 The
following table sets forth the fees paid by the Company for professional services rendered for the audits of the annual financial statements
and fees billed for other services rendered by its current principal accountant, Greengrowth CPAs, prior principal accountants, Gries
& Associates LLC and WWC, P.C.:

 Type of Services Rendered

 2024

 2023

 Audit Fees

 $
 34,250

 $
 36,500

 Audit-Related Fees

 $
 -

 $
 -

 Tax Fees

 $
 -

 $
 -

 All Other Fees

 $
 -

 $
 -

 Pre-approval
Policies

 We
do not have a standing audit committee currently serving and as a result our BOD performs the duties of an audit committee. Our BOD evaluates
and approves, in advance, the scope and cost of the engagement of an accounting firm before the accounting firm renders audit and non-audit
services. We do not rely on pre-approval policies and procedures.

 PART
IV

 ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 (a) (1) Financial Statements.

 Report of Independent Registered Public Accounting Firm Green Growth CPAs (PCAOB ID # 6580)

 Consolidated Balance Sheets as of June 30, 2024 and 2023

 Consolidated Statements of Operations for the Years Ended June 30, 2024 and 2023

 Consolidated Statements of Shareholders' Deficit for the Years Ended June 30, 2024 and 2023

 Consolidated Statements of Cash Flows for the Years Ended June 30, 2024 and 2023

 Notes to Consolidated Financial Statements

 Report of the
Independent Registered Public Accounting Firm

 To the Board of Directors and Shareholders

 of America Great Health

 Disclaimer of Opinion on the Financial Statements

 We were engaged to audit the accompanying balance
sheet of America Great Health (the "Company") as of June 30, 2024 and the related consolidated statements of operations and
comprehensive loss, consolidated statement of changes in stockholders' deficit, and consolidated statement of cash flows for the
year then ended, and the related notes (collectively referred to as the financial statements). As described in the following paragraph,
because the Company did not provide proof of delivery or other evidence of transfer of control necessary to determine whether revenue
was recognized appropriately under ASC 606: Revenue Recognition and failed to provide supporting documentation for expense transactions
for which we were not able to apply other auditing procedures to satisfy ourselves as to the occurrence and valuation of sales and expenses,
we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on the financial statements,
and we do not express, an opinion on these financial statements.

 The Company maintains insufficient documentation
to support the recognition of revenue when performance obligations are satisfied. Additionally, the prices invoiced do not match the agreed-upon
prices in the contracts and/or the prices in the price lists. Further, appropriate documentation to substantiate the existence of expenses
is not available. The Company's records do not permit the application of other auditing procedures to sales or expenses.

 The financial statements of the Company as of
June 30, 2023, were audited by other auditors whose report dated October 12, 2023, expressed an unqualified opinion on those statements.

 Going concern

 The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has
suffered recurring losses from operations and has a shareholder s deficit that raises substantial doubt about its ability to continue
as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.

 Basis for Disclaimer of Opinion

 These financial statements are the responsibility
of the Company's management. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We have served as the Company's auditor
since 2024

 Los Angeles, California

 February 24, 2025

 PCAOB ID Number 6580

 F- 1

Great Health and Subsidiaries

 Consolidated
Balance Sheets

 As of

 As of

 ASSETS

 2024

 2023

 CURRENT ASSETS

 Cash

 $
 54,943

 $
 54,150

 Account receivable, net

 55,100

 -

 Inventory

 83,141

 108,351

 Prepaid and other assets

 32,295

 16,964

 TOTAL CURRENT ASSETS

 225,479

 179,465

 Right-of-use asset, net

 43,260

 41,918

 Due from the related parties

 -

 8,218

 Other assets

 Property and equipment, net

 42,903

 57,692

 TOTAL ASSETS

 $
 323,478

 $
 299,129

 LIABILITIES AND SHAREHOLDERS' DEFICIT

 CURRENT LIABILITIES

 Accounts payable

 $
 1,435,854

 $
 1,450,574

 Income tax payable

 1,685

 3,970

 Short term loan

 606,978

 727,003

 Other payable

 357,472

 241,784

 Due to related party

 1,110,196

 425,142

 Advances from customers

 59,600

 68,331

 Lease liability – current

 21,683

 41,918

 TOTAL CURRENT LIABILITIES

 3,593,468

 2,958,722

 Lease liability – non-current

 21,577

 -

 Accrued liabilities

 186,455

 186,455

 Long term loan

 1,833,577

 1,524,788

 Total Non-Current liabilities

 2,041,609

 1,711,243

 TOTAL LIABILITIES

 5,635,077

 4,669,965

 Commitments and Contingencies

 -

 -

 SHAREHOLDERS' DEFICIT

 Redeemable, convertible preferred stock, 10,000,000 shares authorized: Series A voting preferred stock, zero shares issued and outstanding

 -

 -

 Common stock, no par value, unlimited shares authorized; 21,136,888,326 and 21,107,018,148 shares issued and outstanding

 -

 -

 Additional paid-in capital

 5,019,059

 4,732,477

 Accumulated other comprehensive income

 ( 1,483
)

 ( 500
)

 Accumulated deficit

 ( 10,248,681
)

 ( 9,028,110
)

 Total deficit attributable to owners of the Company

 ( 5,231,105
)

 ( 4,296,133
)

 Non-controlling interest

 ( 80,494
)

 ( 74,703
)

 TOTAL SHAREHOLDERS' DEFICIT

 ( 5,311,599
)

 ( 4,370,836
)

 TOTAL LIABILITIES AND
SHAREHOLDERS' DEFICIT

 $
 323,478

 $
 299,129

 The accompanying notes are an integral part of these consolidated financial statements.

 F- 2

Great Health and Subsidiaries

 Consolidated
Statements of Operations and

 Comprehensive
Loss

 For the Years ended

 2024

 2023

 Sales

 $
 294,670

 $
 204,308

 Cost of goods sold

 124,920

 35,720

 Gross profit

 169,750

 168,588

 Selling, general and administrative expenses

 Selling expense

 95,835

 3,999

 General and administrative expense

 856,615

 657,233

 952,450

 661,232

 Loss from operations

 ( 782,700
)

 ( 492,644
)

 Other income (expenses)

 Interest income

 Interest expense

 ( 443,723
)

 ( 319,705
)

 Other income

 -

 34,983

 ( 443,662
)

 ( 284,696
)

 Loss before income taxes

 ( 1,226,362
)

 ( 777,340
)

 NET LOSS

 $( 1,226,362)

 $
 ( 777,340
)

 BASIC AND DILUTED LOSS PER SHARE

 -

 $
 -

 WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING

 BASIC AND DILUTED

 21,123,253,567

 21,093,402,806

 Non-controlling interest share of loss

 ( 5,791)

 ( 15,920
)

 Net loss attributed to the owners of the Company

 ( 1,220,571
)

 ( 761,420
)

 Foreign currency transaction

 Comprehensive loss

 ( 1,219,588
)

 ( 760,760
)

 The accompanying notes are an integral part of
these consolidated financial statements.

 F- 3

Great Health and Subsidiaries

 Consolidated
Statements of Changes in Shareholders' Accumulated Deficit

 For the Years ended June 30, 2024 and 2023

 Total

 Deficit
Attributable

 Additional

 Accumulated

Other

 Accumulated

Deficit

 to the

 Owners

 Non-

 Total

 Preferred Stock

 Common Stock

 Treasury Stock

 paid-in

 Comprehensive

 During

 of the

 Controlling

 Shareholders'

 Shares

 Amount

 Shares

 Amount

 Shares

 Amount

 Capital

 Income/(Loss)

 Period

 Company

 Deficit

 Balance June 30, 2022

 -

 $

 -

 21,090,218,148

 -

 $

 -

 $

 4,619,992

 $

 $

 ( 8,266,850

)

 $

 ( 3,646,698

)

 $

 ( 58,783

)

 $

 ( 3,705,481

)

 Issuance of common stock for debt

 -

 -

 4,600,000

 -

 -

 -

 -

 -

 Issuance of common stock for compensation

 -

 -

 12,200,000

 -

 -

 -

 -

 -

 -

 Imputed interest

 -

 -

 -

 -

 -

 -

 5,205

 ( 660

)

 -

 4,545

 -

 4,545

 Gain/loss on exchange rate

 -

 -

 -

 -

 -

 -

 -

 -

 -

 Original issue discount on debt

 -

 -

 -

 -

 -

 -

 15,200

 -

 -

 15,200

 -

 15,200

 Net loss

 -

 -

 -

 -

 -

 -

 -

 -

 ( 761,420

)

 ( 761,420

)

 ( 15,920

)

 ( 777,340

)

 Balance June 30, 2023

 -

 $

 -

 21,107,018,148

 $

 -

 -

 $

 -

 $

 4,732,477

 $

 ( 500

)

 $

 ( 9,028,110

)

 $

 ( 4,296,133

)

 $

 ( 74,703

)

 $

 ( 4,370,836

)

 Balance June 30, 2023

 -

 $

 -

 21,107,018,148

 -

 -

 $

 -

 $

 4,732,477

 $

 ( 500

)

 $

 ( 9,028,110

)

 $

 ( 4,296,133

)

 $

 ( 74,703

)

 $

 ( 4,370,836

)

 Issuance of common stock for debt

 -

 -

 8,000,000

 -

 -

 -

 -

 -

 -

 -

 -

 -

 Issuance of common stock for equity investment

 -

 -

 10,500,000

 -

 -

 -

 115,000

 -

 -

 115,000

 -

 115,000

 Issuance of common stock for compensation

 -

 -

 11,370,178

 -

 -

 -

 123,582

 -

 -

 123,582

 -

 123,582

 Treasury Shares

 -

 -

 -

 -

 52,100,000

 -

 -

 -

 -

 -

 Gain/loss on exchange rate

 -

 -

 -

 -

 -

 -

 -

 ( 983

)

 -

 ( 983

)

 -

 ( 983

)

 Original issue discount on debt

 -

 -

 -

 -

 -

 -

 48,000

 -

 -

 48,000

 -

 48,000

 Net loss

 -

 -

 -

 -

 -

 -

 -

 -

 ( 1,220,571

)

 ( 1,220,571

)

 ( 5,791

)

 ( 1,226,362

)

 Balance June 30, 2024

 -

 $

 -

 21,136,888,326

 $

 -

 52,100,000

 $

 -

 $

 5,019,059

 $

 ( 1,483

)

 $

 ( 10,248,681

)

 $

 ( 5,231,105

)

 $

 ( 80,494

)

 $

 ( 5,311,599

)

 The accompanying notes are an integral part of
these consolidated financial statements.

 F- 4

 America Great Health
and Subsidiaries

 Consolidated Statements
of Cash Flows

 Years Ended June 30,

 2024

 2023

 Cash Flows from Operating Activities

 Net loss

 $
 ( 1,226,362
)

 $
 ( 777,340
)

 Adjustments to reconcile net loss to net cash used in operating activities:

 Depreciation

 14,789

 10,346

 Original issue discount

 48,000

 15,200

 Stock compensation

 123,582

 Imputed interest

 -

 5,205

 Provision for inventory obsolescence, net

 9,400

 -

 Payment of lease and rent

 ( 80,438
)

 ( 75,706
)

 Changes in operating Assets and Liabilities:

 Right of use asset – net

 ( 1,342
)

 51,968

 Lease liabilities – net

 47,207

 23,738

 Account receivable – net

 ( 55,100
)

 Prepaid expenses and other assets

 ( 15,331)

 -

 Other long term asset

 -

 2,000

 Inventory

 15,810

 7,709

 Accounts payable and accrued expense

 19,853

 13,050

 Customer advances

 ( 8,731
)

 66,331

 Accrued interest for short term loan

 117,845

 59,356

 Accrued interest for long term loan

 261,789

 237,857

 Other liabilities

 -

 ( 7,863
)

 Income Tax

 Other payable

 112,602

 ( 89,259
)

 Net cash used in operating activities from continuing operations

 ( 615,627
)

 ( 389,809
)

 Net cash used in operating activities

 ( 615,627
)

 ( 389,809
)

 Cash Flows from Investing Activities

 Purchase of property and equipment

 -

 ( 44,420
)

 Net cash used in investing activities

 -

 ( 44,420
)

 Cash Flows from Financing Activities

 Proceeds from issuance of common stock

 115,000

 Proceeds of short term loan

 37,475

 565,216

 Repayment of short term loan

 ( 201,941
)

 ( 43,932
)

 Interest payment to short term loan

 ( 73,403
)

 ( 59,356
)

 Proceeds of long term loan

 60,000

 91,000

 Repayment of long term loan

 ( 10,000
)

 -

 Interest payment to long term loan

 ( 3,000
)

 ( 4,175
)

 Advances from related party

 969,868

 224,422

 Repayment to related party

 ( 276,596
)

 ( 373,140
)

 Net cash provided by financing activities

 617,403

 426,235

 Net increase in cash

 1,776

 ( 7,994
)

 Cash beginning of period

 54,150

 62,643

 Effect of foreign currency translation

 ( 983
)

 ( 499
)

 Cash end of period

 $
 54,943

 $
 54,150

 SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION

 Interest paid

 76,403

 63,531

 Taxes paid

 $

 $

 Non-cash investing and financing information:

 Shares issued for equity investment

 $
 -

 $
 -

 The accompanying notes are an integral part of
these consolidated financial statements.

 F- 5

 AMERICA GREAT HEALTH AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 JUNE 30, 2024 AND 2023

 NOTE 1
 – NATURE OF BUSINESS

 History and Organization

 America Great Health, formerly Crown Marketing,
is a Wyoming corporation (the "Company"). A change of control of the Company was completed on January 19, 2017 from Jay Hooper,
the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000
shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the
Company sold to its former majority shareholder a subsidiary for $ 100 and another subsidiary in exchange for the cancellation of all payables
and accrued expenses. After December 31, 2016, the Company's operations are determined and structured by the new investor group.
As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations.

 On March 1, 2017, the Company filed with the Secretary
of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health.

 On March 9, 2017, the Company formed a wholly owned subsidiary, America
Great Health, under the laws of the State of California.

 On June 24, 2019, the Company registered a wholly
owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition,
investment and financing, and marketing of medical equipment and health products in China.

 On June 30, 2020, the Company and Purecell Group
("Purecell"), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company
agreed to acquire 51 % of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell's
nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day-to-day operation, including
recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. This
transaction was completed in May 2021.

 On December 7, 2020, the Company's wholly-owned
Californian subsidiary, America Great Health, entered into a Cooperation Agreement with Brilliant Healthcare Limited ("Brilliant")
pursuant to which the parties will establish a joint venture in China (the "JV Company") for the purpose of promoting and
developing stem cell related product's R&D, production, sales, raw material procurement, mergers and acquisitions, and consulting
services. After the formation of the JV company is completed, the Company shall invest US$ 4.2 million in the JV Company within the next
24 months for a 60 % equity ownership in the JV Company. Brilliant shall transfer its patented technology to the JV Company as its capital
contribution, to account for a 40 % equity interest in the JV Company. As a condition for AAGH to obtain 60% equity in the JV company and
a as the founder of Brilliant, Dr. Aihua Guo agrees to transfer its patent to the JV company as its share of contribution, and AAGH also
agrees to pay Dr. Aihua Guo additional compensation, which includes: (i) AAGH transfers 300 million original shares of AAGH to Dr. Aihua
Guo at no cost, valuing at $ 15 million; (ii) AAGH pays Dr. Aihua Guo a one-time cash compensation of $ 3 million with the following payment
schedule: AAGH agrees to pay $500,000 to Dr. Aihua Guo six months from the date of signing of this Agreement, $1.5 million to Dr. Aihua
Guo 12 months from the date of signing of this Agreement, and $1 million to Dr. Aihua Guo 24 months from the date of signing of this Agreement.
In June 2021, the JV Company was established in Hainan, China as "Sijinsai (Hainan) Biological Tech Ltd." On July 9, 2021,
the Company paid its first investment of $ 50,000. In July 2021, the Company paid Dr. Aihua Guo $ 100,000 as prepaid investment.

 On May 18, 2021, the Company and David Tsai ("Dr.
Tsai"), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which
Dr. Tsai shall provide to the Company theories, technologies, methods, sources of raw materials, processing and production techniques,
quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin
and activation technology. Dr. Tsai shall also be responsible for the whole process of technology and product production, application
and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity,
promotion and sales. Currently, several patents are in the application process, and several products are in the process of getting ready
for production.

 F- 6

 On September 3, 2021, the Company entered into
an Assets Acquisition Agreement with Wang's Property Investment & Management LLC to purchase 53 units in 19 real estate properties
appraised at $ 7,626,286.37 for a purchase price of $ 7,000,000. The purchase price shall be paid as follows: (i) $1,000,000 on execution
of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary
closing conditions, including, satisfactory due diligence. On September 9, 2021, the Company entered into a Supplemental Assets Acquisition
Agreement with Wang's Property Investment & Management LLC to amend and clarify that (i) it was purchasing 19 real estate properties
which includes 53 units appraised at $ 7,626,286.37 for a purchase price of $ 7,000,000 and (ii) that it will waive and not conduct due
diligence in order for the transaction to proceed. The acquisition has not been consummated.

 On November 4, 2021, the Company set up a 100 % owned subsidiary Nutrature
Health LLC.

 On November 11, 2021, America Great Health (the
"Company") entered into an Advisory Committee Member Consulting Agreement with Dr. Kevin Buckman MD ("Consultant").
Pursuant to the Agreement, Consultant is to provide advisory services, as a member to the Advisory Committee to the Board of Directors
of the Company, including without limitation, assisting GOF Biotechnologies Inc. in its new drug approval process for oral insulin and
Amylase X. Consultant shall be compensated with a warrant to purchase 500,000 shares of the Company at $ 0.01 per share within 24 months
and a warrant at each of the following stages: IND application, Phase I clinical trials, Phase II clinical trials, Phase III clinical
trials and the sale of GOF Biotechnologies Inc. the license of oral insulin and Amylase X at Phase I or Phase II clinical trials stages.
This Agreement shall be for an initial one-year term and shall renew automatically for successive one-year terms up to a maximum of three
(3) years unless terminated by either party pursuant to the Agreement. The 500,000 shares were issued free in April 20, 2022.

 On November 15, 2021, the Company set up a 100 %
owned subsidiary GOF Biotechnologies Inc. GOF is 75 % majority owned ( 60,000,000 shares of common stock) by the Company and the remaining
 25 % of its issued and outstanding shares ( 20,000,000 shares of common stock) are held by Men Hwei, Tsai. On December 31, 2021, the Company
entered into a Supplementary Agreement with Zhigong Lin to amend his prior employment agreement with the Company dated August 31, 2021.
The Supplement Agreements provides, inter alia, that Zhigong Lin would be appointed Chief Executive Officer of GOF. The employment agreement
and supplement agreement were both terminated by the end of July 2022 without the issuance of any GOF shares.

 On February 4, 2021, the Company set up a 100 %
owned subsidiary, International Institute of Great Healthcare, Inc. ("IIGH") under the laws of the State of California. IIGH
will bring together doctors and professional-level experts from different countries and regions in the world to the research fields involving
biomedicine, clinic medicine, health management, information technology, data analysis, software development, artificial intelligence,
industrial planning, financial investment, etc.

 On November 25, 2022, the Company signed a supplementary
agreement with Men Hwei, Tsai who is an unrelated party. The Company A agrees that if the patent is sold or transferred, Men Hwei, Tsai
or Men Hwei, Tsai's successor may receive a 25% gain on the transfer or sale of the interest. The Company agrees to give Men Hwei,
Tsai an additional 20 million AAGH shares. The Company allows Men Hwei, Tsai to use three years (from November 26, 2022 to November 25,
2025) find investors each with more than US$10 million investment. In case that no investor is found within three years, Men Hwei, Tsai
agrees to return the patent to the Company, and both parties will continue to cooperate in accordance with the original contract on May
18, 2021. If Men Hwei, Tsai finds an investor with an investment of at least US$10 million within three years, and the process for Men
Hwei, Tsai and its investors to apply for a new drug may last for several years, then Men Hwei, Tsai agrees that the Company will use
the patented technology to develop dietary supplement that are helpful to Alzheimer's disease. The Company will be responsible for
marketing the dietary supplement. Men Hwei, Tsai is entitled to commission equaling to 8% of sales price.

 On November 26, 2022, the Company signed a supplementary
agreement with Men Hwei, Tsai who is an unrelated party and transferred pending anti-dementia patent to Men Hwei, Tsai for $ 34,978.48.

 Going Concern

 The
accompanying consolidated financial statements ("CFS") were prepared on a going concern basis, which contemplates the
realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the
accompanying CFS, the Company has incurred recurring net losses. For the year ended June 30, 2024, the Company recorded a net loss
of $ 1,226,362, used cash to fund operating activities of $ 615,627, and
on June 30, 2024, had a shareholders' deficit of $ 5,311,599. These factors create substantial doubt about the Company's
ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary if the
Company is unable to continue as a going concern.

 F- 7

 During the year ended June 30, 2017, the Company's
former majority shareholder sold his shares to an investor group. The new owners' plans to continue as a going concern revolve around
its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of
the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the
success of the Company's plan. There is no assurance that the Company will be successful in raising the additional capital or in
achieving profitable operations.

 The
Company's cash needs for the 12 months ended June 30, 2024 were primarily met by loans and advances from the current majority shareholder.
As of June 30, 2024, the Company had a cash balance
of $ 54,943. The Company intends to finance operating costs over the next twelve months with existing cash on hand and advance from the
current majority shareholder.

 NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 Basis of
Presentation

 The accompanying financial statements have been prepared in accordance
with generally accepted accounting principles in the United States of America ("GAAP"), and pursuant to the rules and regulations
of the Securities and Exchange Commission (the "SEC").

 The Company has adjusted certain previously reported amounts in its
balance sheets as of and for the year ended June 30, 2023 to reflect the recording of the advances from customers, netting the corresponding
accumulated deficit for an amount of $ 155,000 which was originally recognized as revenue. This adjustment did not materially impact the
financial position and the result of operations of the Company for the year indicated.

 Basis of Consolidation

 The Consolidated Financial Statements includes
the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California ( 100 %), GOF Biotechnologies
in California ( 75 %), International Institute of Great Health in California ( 100 %), Nutrature Health LLC in California ( 100 %), Sijinsai
in China ( 60 %), US-China Mega Beauty Health Industry Development Co., LTD, ( 100 %), and Peptide Life Inc in California ( 100 %). Intercompany
transactions and accounts were eliminated in consolidation.

 The following table depicts the identity of the Company's subsidiaries:

 Attributable

 Place of

 Equity

 Name of Subsidiary

 Incorporation

 Interest %

 America Great Health in California

 USA

 GOF Biotechnologies in California

 USA

 International Institute of Great Health in California

 USA

 Nutrature Health LLC in California

 USA

 Sijinsai in China

 CHINA

 US-China Mega Beauty Health Industry Development Co., LTD

 CHINA

 Peptide Life Inc in California

 USA

 Estimates

 The preparation of the financial statements in
conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting
period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued
for services, debt and equity investment. Actual results could differ from those estimates.

 Foreign Currency Translation

 Transactions denominated in currencies other than
the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction.
Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency
using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations.

 In
accordance with ASC 830, "Translation of Financial Statements" the subsidiary's assets and liabilities booked and recorded
at the non-US local functional currency are generally translated into USD for consolidation purposes, using the exchange rate on the
balance sheet date, and revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting
from translation of foreign subsidiary's financial statements are recorded as a separate component of accumulated other comprehensive
income within the statement of stockholders' deficit.

 F- 8

 The Company's reporting currency is the
United States Dollar ("USD"). The Company's wholly owned subsidiary of Meizhong Health Industry Development Co., Ltd.
maintains its books and records in its local currency. The Chinese Yuan ("RMB"), which is the functional currency as being
the primary currency of the economic environment in which the subsidiary operates.

 Below is a table with foreign exchange rates used for translation:

 Average Yearly (average rate)

 2024

 Chinese Renminbi (RMB)

 RMB

 7.2139

 United States dollar ($)

 $

 1.00

 Year Ended (Closing rate)

 2024

 Chinese Renminbi (RMB)

 RMB

 7.2674

 United States dollar ($)

 $

 1.00

 Reclassification
of Prior Year Presentations

 Certain prior year accounts and amounts have been
reclassified for consistency with the current year presentation. These reclassifications have no effect on the reported results
of operations. Below is the comparison of the reclassification and the original representation of the related accounts and amounts.

 Consolidated Balance Sheet

 Reclassified

 Original

 2023

 June 30, 2023

 Short term loan

 $

 727,003

 $

 705,216

 Accrued liabilities

 186,455

 609,892

 Deferred income

 -

 223,331

 Advances from customers

 68,331

 -

 Long term loan

 1,524,788

 1,123,138

 Accumulated deficit

 ( 9,028,110

)

 ( 9,183,110

)

 Total

 $

 ( 6,521,533

)

 ( 6,521,533

)

 Consolidated Statement of Cash Flows

 Reclassified

 Original

 June 30, 2023

 June 30, 2023

 Proceed from issuance of common stocks

 $

 $

 92,080

 Payment of leases and rent

 ( 75,706

)

 -

 Right of use asset – net

 51,968

 -

 Lease liabilities – net

 23,738

 -

 Stock based comprehension

 -

 Short term loan

 -

 521,284

 Short term loan – proceeds

 565,216

 -

 Short term loan – repayment

 ( 43,932

)

 -

 Accrued interest for short term loan

 59,356

 -

 Short term loan – interest paid

 ( 59,356

)

 -

 Income tax payable

 -

 Other payable

 ( 89,259

)

 ( 88,459

)

 Long term loan

 -

 324,682

 Long term loan – proceeds

 91,000

 -

 Accrued interest for long term loan

 237,857

 -

 Long term loan – interest paid

 ( 4,175

)

 -

 Advances from related parties

 224,422

 ( 148,718

)

 Repayment to related parties

 ( 373,140

)

 -

 Total

 $

 700,869

 $

 700,869

 F- 9

 Cash

 The Company considers all highly liquid debt instruments
purchased with maturity periods of three months or less to be cash equivalents. The carrying amounts reported in the accompanying balance
sheet for cash and cash equivalents approximate their fair value. The Company's bank account in the United States is protected by
FDIC insurance.

 The
Company's bank account in the United States is protected by FDIC insurance. As of June 30, 2024 and 2023, the Company's bank
account in the United States had $ 9,355 and $ 4,131, respectively,
under FDIC insurance of $ 250,000.

 Revenues

 Revenue from sale of goods under Topic 606,
Revenue from Contracts with Customers, is recognized in a manner that reasonably reflects the delivery of the Company's products
and services to customers in return for expected consideration and includes the following elements:

 executed contract(s) with customers that the Company believes is legally enforceable;

 identification of performance obligation in the respective contract;

 determination of the transaction price for each performance obligation in the respective contract;

 allocation of the transaction price to each performance obligation; and

 recognition of revenue only when the Company satisfies each performance obligation.

 The Company sells health-related products through
wholesale and retailers. The Company considers purchase orders to be a contract with a customer. Contracts with customers are considered
to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one
year, and virtually all of the Company's contracts are short-term. The Company recognizes revenue for the transfer of promised goods
to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The
Company typically satisfies its performance obligations in contracts with customers upon shipment of the goods. The Company usually does
not have any contract assets since the Company has an unconditional right to consideration when the Company has satisfied its performance
obligation and payment from customers is not contingent on a future event. Generally, payment is due from customers within 40 to 60 days
of the invoice date and 180 days for a major customer, and the contracts do not have significant financing components nor variable consideration.
Returns and allowances are not a significant aspect of the revenue recognition process as historically they have been immaterial. All
of the Company's contracts have a single performance obligation satisfied at a point in time and the transaction price is stated
in the contract, usually as a price per unit. All estimates are based on the Company's historical experience; complete satisfaction
of the performance obligation, and the Company's best judgment at the time the estimate is made. Historically, sales returns have
not significantly impacted on the Company's revenue.

 F- 10

 Product Revenue

 A majority of the Company's sales are for
products sold at a point in time when shipped to customers, for which control is transferred to the customer as goods are delivered to
the third-party carrier for shipment. The Company receives payment for the sale of products at the time customers place orders and payment
is required prior to shipment. Any payment received prior to shipment is recognized as a contract liability under the account deferred
revenue. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer.

 Shipping and handling activities are performed
by third-party carriers for shipment. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes
the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in the cost of sales
for all periods presented.

 Account Receivable

 The Company has been developing its new products and launching large-scale
production since November 2023. As of June 30, 2024 net accounts receivable amounted to $ 55,100.

 The Company has not established a reserve for uncollectible amounts
on the newly launched products since the historical data on bad debts in the aging categories of the new products could not support such
estimates. For the year ended June 30, 2024, the Company has $ 23,400 of allowance for bad debt.

 Inventories

 Inventories
are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net
realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. For the year ended June 30, 2024, the
Company has $ 9,400 of inventory valuation reserve.

 At the end of fiscal years 2024 and 2023, inventories
comprised:

 2024

 2023

 Raw materials

 $

 56,435

 $

 62,348

 Finished goods

 36,106

 46,003

 Inventory valuation reserve

 ( 9,400

)

 -

 Subtotal

 $

 83,141

 $

 108,351

 Cost of Goods Sold

 The cost of
goods sold includes product costs only and is recorded in the same period in which related revenues have been recorded.

 Property and Equipment

 Property and equipment are stated at cost less
accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets.

 Machinery and equipment

 5 years

 At the end of fiscal years 2024 and 2023, machinery and equipment at
cost and accumulated depreciation were:

 2024

 2023

 Machinery and equipment

 $

 73,943

 $

 73,943

 Accumulated depreciation

 ( 31,040

)

 ( 16,251

)

 Subtotal

 $

 42,903

 $

 57,692

 Equity
Method Investments

 We
apply the equity method of accounting to investments when we have significant influence, but not controlling interest in the investee.
Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest,
representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company's
proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned "equity
investment" in our Consolidated Statements of Operations. The carrying value of our equity method investments is reported in equity
investment in the Consolidated Balance Sheets. The Company's equity method investments are reported at cost and adjusted each period
for the Company's share of the investee's income or loss and dividend paid, if any. The Company's share of the investee's
income or loss is recorded on a one quarter lag for all equity method investments. The Company classifies distributions received from
equity method investments using the cumulative earnings approach on the Consolidated Statements of Cash Flows. The Company assesses investments
for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.

 F- 11

 Fair Value Measurements

 Fair value measurements are determined using authoritative
guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities
as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer
a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three
broad levels as follows:

 Level
1—Quoted prices in active markets for identical assets or liabilities.

 Level
2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

 Level
3—Unobservable inputs based on the Company's assumptions.

 The Company is required to use observable market data if available
without undue cost and effort.

 The Company's financial instruments include
cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.

 Stock-based Compensations

 The Company offers restricted stock-based compensations
to the employees and contractors. All stock-based compensations are measured based on their values and are expensed over the period during
which an employee or a contractor is required to provide service in exchange for the compensations.

 Treasury Stock Shares

 Treasury shares are recognized at acquisition
cost and are presented as a deduction from shareholder's equity. Upon sale of treasury shares, the realized gain or loss is recognized
through the income statement as income or expense from financial assets.

 Loss Per Share

 Basic earnings (loss) per share are computed by
dividing the income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss)
per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional
common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were
dilutive. The Company's diluted loss per share is the same as the basic loss per share for the years ended June 30, 2024 and 2023,
as there are no potential shares outstanding that would have a diluted effect.

 F- 12

 Income Taxes

 Income
tax expenses are based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax
consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances
are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.

 The Company accounts for uncertainty in income
taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for
recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained
on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the
largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax
benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related
to uncertain tax positions are recognized in the provision for income taxes.

 Recent Accounting Pronouncements

 In July 2023, the FASB issued Accounting Standard
Update ("ASU") No. 2023-03, Presentation of Financial Statements (Topic 205), Income Statement - Reporting Comprehensive Income
(Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation – Stock Compensation (Topic
718). As ASU 2023-03 did not provide any new guidance, there was no transition or effective date associated with its adoption. Accordingly,
the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03 did not have any impact on the Company's
consolidated financial statement presentation or related disclosures.

 In December 2023, the FASB issued ASU No. 2023-09
(ASU 2023-09), Income Taxes (Topic 740): Improvements to Income Tax Disclosures to enhance the transparency and decision usefulness of
income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption
is permitted. As the amendments apply to income tax disclosures only, the Company does not expect adoption to have a material impact on
our consolidated financial statements.

 Management does not believe that any other recently issued, but not
yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company's financial statement presentation
or disclosures.

 NOTE 3 – OTHER ASSET

 As of June
30, 2024 and 2023, other assets amounted to $ 11,836 for both
years. Other assets consist of the following:

 2024

 2023

 Rent deposits

 Total

 NOTE 4 – RELATED PARTY TRANSACTIONS

 During
the year ended June 30, 2024, the Company's current majority shareholder advanced $ 969,868 to
the Company as working capital and the Company repaid $ 276,596 to the shareholder. As of June 30, 2024 and 2023, the Company owed
its current shareholder of $ 1,110,196 and $ 425,142 respectively. The
advances are non-interest bearing and are due on demand. Imputed interest amounted to $- and $ 5,205 for
the years ended June 30, 2024 and 2023 and was recorded as paid in capital, respectively.

 F- 13

 NOTE 5 – SHORT TERM LOAN

 As
of June 30, 2024 and 2023, short term loan principals amounted to $ 540,750 and $ 705,216 from unrelated third parties, respectively.
As of June 30, 2024, the Company paid off $ 150,000 to
the loan received on January 13, 2023.

 Short Term Loans

 As of June 30, 2024

 As of June 30, 2023

 Receiving
 Date

 Maturity
 Date

 Accrued
 Liability

 Total

 Accrued
 Liability

 Total

 2024
 Annualized
 percentage
 rate

 1/13/2023

 1/13/2024

 $
 --

 $
 27,200

 $
 27,200

 $
 150,000

 $
 5,809

 $
 155,809

 %

 1/19/2023

 1/18/2024

 300,000

 39,028

 339,028

 300,000

 15,978

 315,978

 %

 2/6/2023

 7/2/2024

 -

 15,216

 -

 15,216

 %

 2/25/2023

 6/24/2023

 -

 -

 %

 3/1/2023

 8/31/2023

 -

 -

 %

 3/1/2023

 8/31/2023

 -

 -

 %

 3/1/2023

 9/30/2023

 -

 -

 %

 3/1/2023

 9/30/2023

 -

 -

 %

 Total

 $
 540,750

 $
 66,228

 $
 606,978

 $
 705,216

 $
 21,787

 $
 727,003

 NOTE 6 – LONG TERM LOAN

 As
of June 30, 2024 and 2023, long term loan principals amounted to $ 1,173,138 and $ 1,123,138, respectively. The loan has an annual interest
rate of 20 %. The principal and interest are due in five years from the original dates of the loans. Interest expenses of the long-term
loans incurred for the years ended June 30, 2024 and 2023 amounted to $ 222,745 and $ 212,704, respectively. As of June 30, 2024, the Company
paid off $ 10,000 to the loan received on September 30, 2021 and $ 3,000 interest as well.

 Most long-term loans are pledged with the Company's
stocks as collateral again the loans. As of June 30, 2024, total stocks pledged with the long-term loans is 32,656,840 shares.

 As
of June 30, 2024, long term loan consisted of the following:

 Shares
 pledged

 Accrued
 interest

liability

 Balance

 Received long term loan on April 27, 2021

 10,000,000

 $
 200,000

 $
 127,123

 $
 327,123

 Received long term loan on June 3, 2021

 3,050,000

 290,000

 178,449

 468,449

 Received long term loan on June 4, 2021

 30,767

 80,767

 Received long term loan on June 23, 2021

 300,000

 18,132

 48,132

 Received long term loan on July 12, 2021

 80,000

 5,940

 15,940

 Received long term loan on September 1, 2021

 1,540,000

 60,000

 33,962

 93,962

 Received long term loan on September 22, 2021

 27,726

 77,726

 Received long term loan on September 27, 2021

 27,589

 77,589

 Received long term loan on October 29, 2021

 161,840

 12,138

 6,485

 18,623

 Received long term loan on November 9, 2021

 26,411

 76,411

 Received long term loan on November 16, 2021

 1,400,000

 140,000

 73,414

 213,414

 Received long term loan on November 18, 2021

 26,164

 76,164

 Received long term loan on November 29, 2021

 200,000

 20,000

 10,345

 30,345

 Received long term loan on November 30, 2021

 5,167

 15,167

 Received long term loan on October 13, 2022

 2,625,000

 21,000

 7,203

 28,203

 Received long term loan on March 10, 2023

 1,000,000

 2,620

 12,620

 Received long term loan on March 14, 2023

 1,000,000

 2,597

 12,597

 Received long term loan on March 16, 2023

 1,000,000

 2,586

 12,586

 Received long term loan on April 17, 2023

 6,000,000

 7,233

 37,233

 Received long term loan on May 9, 2023

 1,000,000

 2,290

 12,290

 Received long term loan on June 24, 2021

 600,000

 60,000

 38,236

 98,236

 Total

 32,556,840

 $
 1,173,138

 $
 660,439

 $
 1,833,577

 F- 14

 The principal balance, the scheduled principal
payments, the schedule interest payments, and the weighted average interest rates of the long-term loan future maturities are as follows:

 Year Ending June 30

 Balance

 Scheduled

 Payments

 Schedule

 Payments

 Weighted

 Average

 Rate

 2025

 1,173,138

 -

 234,628

 20.00
 %

 2026

 473,138

 700,000

 112,883

 9.62
 %

 2027

 21,000

 452,138

 67,413

 14.25
 %

 2028

 -

 21,000

 3,057

 14.56
 %

 NOTE 7 – CONVERTIBLE, REDEEMABLE PREFERRED STOCK

 During the year ended June 30, 2016, the Company's
Board of Directors authorized the creation of a series of preferred stock consisting of 1,000,000 shares designated as Series A Preferred
Stock (the "Series A"). The Series A is entitled to a dividend of 4 %, when and as declared, and is entitled to a liquidation
preference of $ 1 per share plus unpaid dividends. The Series A is redeemable at the option of the Company at any time, in whole or in
part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the "Stated Value"). In the event
of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to
a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series
A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate
(the "Conversion Rate"), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market
Price for the purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading
days.

 The Series A is also subject to adjustments to
the Conversion Rate. If the common stock issuable on conversion of the Series A is changed into the same or a different number of shares
of any other class or classes of stock, whether by capital reorganization, reclassification, or otherwise (other than a subdivision or
combination of shares provided for above), the holders of the Series A shall, upon its conversion, be entitled to receive, in lieu of
the common stock which the holders would have become entitled to receive but for such change, a number of shares of such other class or
classes of stock that would have been subject to receipt by the holders if they had exercised their rights of conversion of the Series
A immediately before that change.

 In August 2016, the Company filed an amendment
to its Articles of Incorporation to increase the number of authorized shares of Series A Preferred Stock from 1,000,000 to 10,000,000.

 There were no preferred shares outstanding as of June 30, 2024 and
2023.

 NOTE 8
– STOCK BASED COMPENSATION

 The Company sometimes issues common stock to employees,
contractors and consultants for services rendered.

 The Company accounts for stock-based payments
to employees, contractors and consultants by measuring the cost of services received in exchange for equity awards utilizing the grant
date fair value of the awards, with the cost recognized as compensation expense.

 The Company recognizes the fair value of stock-based compensation awards
in payroll if it is for employees, and operating costs if it is for contractors and consultants, as appropriate, in the Company's
consolidated statements of operations.

 The Company
issued 11,370,178 shares to one of its employees as stock
compensation during the year of 2024, total amount of $ 123,582.

 F- 15

 NOTE 9
 – TREASURY STOCK SHARES

 On January 22, 2024, the Company issued 52,100,000 shares of common
stock to Top Professional Management Group Inc. in exchange for 51 % of the control shares. However, due to the incomplete internal due
diligence process, the investment was temporarily suspended, and the Board of Directors withheld the certificate for further evaluation.
As a result, the Company recorded 52,100,000 shares of common stock as treasury stock as of June 30, 2024.

 NOTE 10 – SHAREHOLDERS' DEFICIT

 On June 30, 2024 and 2023, the Company had 21,136,888,326 and 21,107,018,148
shares of common stock issued and outstanding, respectively.

 1) Shares issued for equity investment

 On
April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000
shares that is 5 % of Imediplus. The transaction has not been completed by the reporting date.

 Equity
Investments:

 On June 30, 2020, the Company and Purecell Group
("Purecell"), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company
agreed to acquire 51 % of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell's
nominated trustee. Because the company does not have significant control over Purecell, this is an equity investment. Upon completion
of the acquisition transaction, Purecell shall remain autonomy in its day-to-day operation, including recruiting and retaining management
team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued
 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell") in exchange for 51 % of ownership of Purecell.
On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell's project introducer as compensation for services,
at fair market value of $ 0.00001 per share.

 On May 11, 2021, Aussie Produce PTY LTD ("AP")
signed an agreement with Purecell to invest $ 2,340,000 in exchange of 6 % of total outstanding shares of Purecell and 35,000,000 shares
of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $ 2,340,000 investment. In addition, Purecell
will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue an additional 31,212,000 shares to
Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000
shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in
place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000
shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholders of AP, at fair market value of $ 0.00001 per share.

 On March 31, 2022, the Company issued 1,300,000 shares of common stock
to an US individual at $ 0.075 per share.

 On
November 22, 2023, the Company issued 8,000,000
 shares of common stock
at $ 0.010 per share to four investors.

 On November 24, 2023, the Company issued 1,000,000 shares of common
stock at $ 0.020 per share to one investor.

 On January 2, 2024, the Company issued 1,000,000 shares of common stock
at $ 0.010 per share to one investor.

 On January 16, 2024, the Company issued 500,000 shares of common stock
at $ 0.010 per share to one investor.

 On January
22, 2024, the Company issued 52,100,000 shares of common
stock to Top Professional Management Group Inc. for its 51 % of control shares. However, due to the incomplete internal due diligence
process, the investment was temporarily suspended, and the Board of Directors withheld the certificate for further evaluation.
 These shares are held in treasury.

 2) Shares issued for stock compensation

 On
October 30, 2023, the Company issued an aggregate of 6,488,867 shares of common stock to three unrelated parties as compensation for
services. The issuance of these shares is recorded at a fair market value of $ 25,956.

 On
January 22, 2024, the Company issued 4,881,311 shares of common stock to an unrelated party as compensation for services. The
issuance of these shares is recorded at a fair market value of $ 97,626.

 3) Shares issued for loans as original issue discount

 On
October 30, 2023, the Company issued 7,000,000 shares of restricted common stock free to three unrelated parties' long-term
loans (three years) of $ 40,000. The issuance of these shares is as the collateral of the corresponding loans and is recorded at a
fair market value of $ 28,000 or at $ 0.02 per share.

 On
January 22, 2024, the Company issued 1,000,000 shares
of restricted common stock free to an unrelated party to extend a short-term loan (six month) of $ 40,000 dated March 1, 2023. The issuance
of these shares is recorded at a fair market value of $ 20,000 or at $ 0.02 per share.

 F- 16

 NOTE 11 – EQUITY INVESTMENT

 On June 30, 2020, the Company and Purecell Group
("Purecell"), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company
agreed to acquire 51 % of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell's
nominated trustee. Becausethe company does not have significant control over Purecell, so this is an equity investment. Upon completion
of the acquisition transaction, Purecell shall remain autonomy in its day-to-day operation, including recruiting and retaining management
team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued
 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell") in exchange of 51 % of ownership of Purecell.
On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell's project introducer as compensation for services,
at fair market value of $ 0.00001 per share.

 On May 11, 2021, Aussie Produce PTY LTD ("AP")
signed an agreement with Purecell to invest $ 2,340,000 in exchange of 6 % of total outstanding shares of Purecell and 35,000,000 shares
of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $ 2,340,000 investment. In addition, Purecell
will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell.
Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares
of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place,
the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares
for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP, at fair market value of $ 0.00001 per share.

 The following table summarizes the income statement of Purecell.

 From date of

 From date of

 equity

 equity

 Investment

 to

 investment

 to

 06/30/2024

 06/30/2023

 Sales

 $
 61,457

 $
 270,931

 Gross profit

 61,457

 246,441

 Net loss

 ( 294,904
)

 ( 307,359
)

 51 % share

 $
 ( 150,401
)

 $
 ( 156,753
)

 The following table provides the summary of balance sheet information for Purecell. Because the 51 % of Purecell losses exceeded the investment the Company made to Purecell, the value of investment is zero,

 As of

 As of

 2024

 2023

 Total assets

 $

 3,092,663

 $

 3,192,224

 Net assets

 2,021,541

 2,203,484

 51 % ownership

 1,030,986

 1,231,113

 Beginning balance of investment, May 11, 2021

 5,450

 5,450

 Loss on equity investment - accumulated

 ( 5,450

)

 ( 5,450

)

 Ending balance of investment, June 30, 2024

 -

 F- 17

 NOTE 12 – INCOME TAXES

 Deferred taxes represent the net tax effects of
the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences
result primarily from the recording of tax benefits of net operating loss carry forwards.

 As of June 30, 2024, the Company has an insufficient
history to support the likelihood of ultimate realization of the benefit associated with the deferred tax asset. Accordingly, a valuation
allowance has been established for the full amount of the net deferred tax asset.

 Under the Provisional Regulations of The People's
Republic of China Concerning Income Tax on Enterprises promulgated by the PRC, which took effect on January 1, 2008, domestic and foreign
companies pay a unified corporate income tax of 25 %, except for a 15 % corporate income tax rate for qualified high technology and science
enterprises.

 The Company's effective income tax rate
differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes for the years ended June
30, 2024 and 2023 as follows:

 Year Ended June 30,

 2024

 2023

 Income tax benefit at federal statutory rate-US

 %

 %

 State tax, net of fed effect-US

 %

 %

 Change in valuation allowance-US

 ( 28
)%

 ( 28
)%

 Income tax benefit at federal statutory rate-PRC

 %

 %

 Change in valuation allowance-PRC

 ( 25
)%

 ( 25
)%

 The components
of deferred taxes consist of the following at June 30, 2024 and 2023:

 2024

 2023

 Net operating loss carryforwards

 $

 7,924,234

 $

 6,697,872

 Less: valuation allowance

 ( 7,924,234

)

 ( 6,697,872

)

 Net deferred tax assets

 $

 -

 $

 -

 As of June 30, 2024, the Company had federal and
California income tax net operating loss carryforwards of $ 7,924,234. These net operating losses originating in tax years beginning prior
to Jan. 1, 2018, will begin to expire 20 years from the date the tax returns are filed. The net operating losses originating in tax years
beginning after Jan. 1, 2018, will be carried forwarded indefinitely.

 NOTE 13
 – LEASE

 The Company has a month-to-month leases agreement
with GKT, Alhambra, LP after the prior lease expired on November 30, 2023. The current monthly rent including monthly management fee is
$ 4,939.17.

 The
Company has entered into an operating lease agreement with SoCal Industrial LLC, Irwindale. The lease term of the office space is from
June 1, 2024 to May 31, 2026 after the prior lease expired on May 31, 2024. The current monthly rent including monthly management fee
is $ 1,940.40. The operating lease is listed as a separate line item on the Company's consolidated
financial statements and represents the Company's right to use the underlying asset for the lease term. The Company's obligation
to make lease payments is also listed as a separate line item on the Company's condensed consolidated financial statements.

 Operating
lease right-of-use assets and liabilities commencing are recognized at commencement date based on the present value of lease
payments over the lease term. For the year ended June 30, 2024, the Company recognized approximately $ 80,438 in total lease
costs.

 Because the rate implicit in each lease is not
readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments.

 F- 18

 Information related to the Company's operating ROU assets and related lease liabilities are as follows:

 Year Ended

 2024

 Cash paid for operating lease liabilities

 $
 80,438

 Weighted-average remaining lease term

 1.92

 Weighted-average discount rate

 %

 Minimum future lease payments

 $
 45,475

 The following table presents the amortization of the Company's
lease liabilities under ASC 842 for each of the following years ending June 30:

 2025

 $
 23,355

 2026

 22,120

 Total minimum payments

 45,475

 Less: imputed interest

 ( 2,215
)

 Total lease liability

 43,260

 Less: short-term lease liability

 ( 21,683
)

 Long-term lease liability

 $
 21,577

 NOTE 14 – CONCENTRATION

 Major vendors

 For the year ended June 30, 2024, no vendors accounted
for 10% or more of the Company's purchases and its outstanding accounts payable balances as at year-end dates.

 NOTE 15
 – SUBSEQUENT EVENTS

 On August 26, 2024, America Great Health (the "Company")
entered into an International Agency Agreement (the "Agreement") with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company
("Yunchi"). Under this Agreement, the Company has appointed Yunchi as its exclusive agent to promote and sell Ionic Peptide
products within Yunnan Province, China, for a term of three years. According to the Agreement, the target sales are set at $ 1 million
for the first year following the execution of the Agreement, with $ 5 million targeted for both the second and third years. Furthermore,
Yunchi holds the exclusive rights to market and sell the products within Yunnan Province during the contract term. Form 8-K for this agreement
was released on August 30, 2024

 On September 02, 2024, the International Institute of Great Health,
Inc. (the "Company"), a wholly owned subsidiary of America Great Health, entered into a Technology Contract for Commissioned
Development (the "Contract") with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company ("Yunchi"). Under the
Contract, Yunchi has engaged the Company to provide specialized technical development for its ionic peptide project using liquor distiller's
grains and will compensate the Company for these services. The development involves the Company's proprietary, patented protein
peptide surface ion modification, transformation, and activation technology, which will be applied to Yunchi's existing liquor tank
raw materials. This process will not only preserve the original properties of the materials but also add the ability to inhibit the growth
of cancer cells in vitro. According to the Contract, the technology development will take place in a laboratory in the United States,
while the experimental base will be in China. The development period is set for three (3) months. Form 8-K for this contract was released
on September 9, 2024.

 On September 02, 2024, the International Institute of Great Health,
Inc. (the "Company"), a wholly owned subsidiary of America Great Health, entered into a Technology Contract for Commissioned
Development (the "Contract") with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company ("Yunchi"). Under the
Contract, Yunchi has engaged the Company to provide specialized technical development for its Ganoderma lucidum ionic peptide project
and will compensate the Company for these services. The development involves the Company's proprietary, patented protein skin surface
ion modification, transformation technology, which will be applied to Yunchi's existing Ganoderma lucidum raw materials. This process
will not only preserve the original properties of the materials but also add the ability to inhibit the growth of cancer cells in vitro.
According to the Contract, the technology development will take place in a laboratory in the United States, while the experimental base
will be in China. The development period is set for three (3) months. Form 8-K for this contract was released on September 16, 2024.

 On September 16, 2024, the International Institute of Great Health,
Inc. (the "Company"), a wholly owned subsidiary of America Great Health, entered into a Technology Contract for Commissioned
Development (the "Contract") with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company ("Yunchi"). Under the
Contract, Yunchi has engaged the Company to provide specialized technical development for its bird's nest ionic peptide project
and will compensate the Company for these services. The development involves the Company's proprietary, patented protein skin surface
ion modification, transformation technology, which will be applied to Yunchi's existing bird's nest raw materials. This process
will not only preserve the original properties of the materials but also add the ability to inhibit the growth of cancer cells in vitro.
According to the Contract, the technology development will take place in a laboratory in the United States, while the experimental base
will be in China. The development period is set for two and a half (2.5) months. Form 8-K for this contract was released on September
25, 2024.

 F- 19

 On September 22, 2024, America Great Health (the "Company")
entered into a Framework Agreement for Product Project Cooperation (the "Contract") with Aide Huhuan (Chengdu) Enterprise
Management, Co. Ltd., a Chinese company ("Aide Huhuan"). The Company's products are a series of ion peptide products
developed using "protein surface ion modification technology," achieving a world-leading position in both research and production.
Aide Huhuan, with its strategic location in Chengdu, China, has the advantage of nationwide market reach, including access to multiple
hospital preparation channels and an extensive marketing network. Under the Contract, Aide Huhuan will utilize its market resources to
promote and sell the ion protein peptide products developed by the Company, thereby expanding market share. Both parties will collaborate
on technical exchanges and cooperation in the field of biotechnology. The Company guarantees that its products meet the necessary compliance
qualifications for entry into the Chinese market and will provide high-quality ion protein peptide products that adhere to relevant standards.
Additionally, the Company will offer Aide Huhuan product training and technical support to help them effectively promote and sell the
products in China. Form 8-K for this contract was released on September 30, 2024.

 On September 24, 2024, the International Institute of Great Health,
Inc. (the "Company"), a wholly owned subsidiary of America Great Health, entered into a Technology Contract for Commissioned
Development (the "Contract") with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company ("Yunchi"). Under the
Contract, Yunchi has engaged the Company to provide specialized technical development for its Panax notoginseng peptide project and will
compensate the Company for these services. The development involves the Company's proprietary, patented protein skin surface ion
modification, transformation technology, which will be applied to Yunchi's existing Panax notoginseng peptide raw materials. This
process will not only preserve the original properties of the materials but also add the ability to inhibit the growth of cancer cells
in vitro. According to the Contract, the technology development will take place in a laboratory in the United States, while the experimental
base will be in China. The development period is set for three (3) months. Form 8-K for this contract was released on October 4, 2024.

 On September 20, 2024, the International Institute of Great Health,
Inc. (the "Company"), a wholly owned subsidiary of America Great Health, entered into a Technology Contract for Commissioned
Development (the "Contract") with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company ("Yunchi"). Under the
Contract, Yunchi has engaged the Company to provide specialized technical development for its sea cucumber ion peptide project and will
compensate the Company for these services. The development involves the Company's proprietary, patented protein skin surface ion
modification, transformation technology, which will be applied to Yunchi's existing sea cucumber raw materials. This process will
not only preserve the original properties of the materials but also add the ability to inhibit the growth of cancer cells in vitro. According
to the Contract, the technology development will take place in a laboratory in the United States, while the experimental base will be
in China. The development period is set for three (3) months. Form 8-K for this contract was released on October 8, 2024.

 From August 9, 2024 to September 15, 2024, one investor paid $ 68,000
to purchase 5,200,000 common shares. The transfer agent has not issued these shares until the issuance of this report.

 On October 30, 2024, another investor paid $ 9,116 to purchase 1,823,282
common shares. The transfer agent has not issued these shares until the issuance of this report.

 On September 20, 2024, the Company signed a service agreement of fund-raising service with an
unrelated person and beside the service fees of $ 8,000, he will receive 6,800,000 common shares as a bonus.

 F- 20

 (b)
Exhibits. The following exhibits of the Company are included herein.

 2.1

 Agreement and Plan of Reorganization between the Company and Okra Energy, Inc. dated December 2, 2013 (1).

 3.1

 Articles of Incorporation (2)

 3.2

 Articles of Merger (3)

 3.3

 Bylaws (2)

 3.4

 Amended and Restated Articles of Incorporation, as filed June 24, 2016 (4)

 3.5

 Amendment to Articles of Incorporation increasing authorized Series A Preferred, August 20, 2016 (4)

 3.6

 Articles of Amendment (5)

 31.1

 Certification by the P resident and the Secretary. Filed
herewith.

 31.2

 Certification by the Financial Officer. Filed herewith.

 32.1

 Certifications by the Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, File
herewith.

 32.2

 Certifications by the Principal Financial Officer Pursuant to 18 U.S.C. Section 1350. File
herewith.

 101.INS

 101.SCH

 101.CAL

 101.DEF

 101.PRE

 101.LAB

 1.
 filed with Current Report on Form 8-K filed December 5, 2013

 2.
 filed with Registration Statement on Form S-1 filed September 9, 2011.

 3.
 filed with Amendment No. 1 to Registration Statement on Form S-1 dated October 14, 2011.

 4.
 filed with Annual Report on Form 10-K filed December 16, 2016.

 5.
 filed with Current Report on Form 8-K filed May 17, 2017.

 SIGNATURES

 Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

 AMERICA GREAT HEALTH

 Date: February 24, 2025

 /s/ Quinn Chen

 Quinn
 Chen, Chief Financial Officer

 Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

 Date: February 24, 2025

 /s/
 Mike Q. Wang

 Mike Q. Wang, President, Chief Executive
 Officer,

 Secretary and Director

 0001098009 false FY 0

 2024-09-30

 2023-12-31

 us-gaap: TreasuryStockCommonMember

 us-gaap: TreasuryStockCommonMember

 2024-04-01

 2017-01-19
 2017-01-19

 us-gaap: CorporateJointVentureMember

 aagh: JVCompanyMember

 aagh: BrilliantHealthcareLimitedMember

 us-gaap: CoVenturerMember

 us-gaap: CashDistributionMember
 us-gaap: CoVenturerMember

 2021-07-09
 2021-07-09

 us-gaap: CoVenturerMember

 2021-07-01
 2021-07-31

 2021-09-03

 2021-09-03
 2021-09-03

 aagh: NutratureHealthLLCMember

 2021-11-04

 2021-11-11
 2021-11-11

 2021-11-11

 2022-04-20
 2022-04-20

 aagh: GofBiotechnologiesIncMember

 2021-11-15

 aagh: GofBiotechnologiesIncMember

 2021-11-15

 2021-11-15

 aagh: InternationalInstituteOfGreatHealthIncIIGHMember

 2021-02-04

 2022-11-25
 2022-11-25

 2022-11-26

 srt: RevisionOfPriorPeriodErrorCorrectionAdjustmentMember

 aagh: AmericaGreatHealthCaliforniaMember

 aagh: GOFBiotechnologiesInCaliforniaMember

 aagh: InternationalInstituteOfGreatHealthMember

 aagh: NutratureHealthLLCMember

 aagh: SijinsaiMember

 aagh: USChinaMegaBeautyHealthIndustryDevelopmentCoLTDMember

 aagh: PeptideLifeIncInCaliforniaMember

 aagh: AmericaGreatHealthCaliforniaMember

 aagh: GOFBiotechnologiesInCaliforniaMember

 aagh: InternationalInstituteOfGreatHealthMember

 aagh: NutratureHealthLLCMember

 aagh: SijinsaiMember

 aagh: USChinaMegaBeautyHealthIndustryDevelopmentCoLTDMember

 aagh: PeptideLifeIncInCaliforniaMember

 currency: CNY
 aagh: IncomeStatementItemsMember

 currency: USD
 aagh: IncomeStatementItemsMember

 currency: CNY
 aagh: BalanceSheetItemsMember

 currency: USD
 aagh: BalanceSheetItemsMember

 srt: RestatementAdjustmentMember

 srt: ScenarioPreviouslyReportedMember

 srt: RestatementAdjustmentMember

 srt: ScenarioPreviouslyReportedMember

 us-gaap: MachineryAndEquipmentMember

 us-gaap: MachineryAndEquipmentMember

 us-gaap: MajorityShareholderMember

 us-gaap: MajorityShareholderMember

 us-gaap: MajorityShareholderMember

 us-gaap: MajorityShareholderMember

 us-gaap: ShortTermDebtMember

 us-gaap: ShortTermDebtMember

 aagh: LoanReceivedOnJanuary132023Member

 aagh: LoanReceivedOnJanuary132023Member

 aagh: LoanReceivedOnJanuary132023Member

 aagh: LoanReceivedOnJanuary132023Member

 aagh: LoanReceivedOnJanuary192023Member

 aagh: LoanReceivedOnJanuary192023Member

 aagh: LoanReceivedOnJanuary192023Member

 aagh: LoanReceivedOnJanuary192023Member

 aagh: LoanReceivedOnFebruary62023Member

 aagh: LoanReceivedOnFebruary62023Member

 aagh: LoanReceivedOnFebruary62023Member

 aagh: LoanReceivedOnFebruary62023Member

 aagh: LoanReceivedOnFebruary252023Member

 aagh: LoanReceivedOnFebruary252023Member

 aagh: LoanReceivedOnFebruary252023Member

 aagh: LoanReceivedOnFebruary252023Member

 aagh: LoanReceivedOnMarch012023Member

 aagh: LoanReceivedOnMarch012023Member

 aagh: LoanReceivedOnMarch012023Member

 aagh: LoanReceivedOnMarch012023Member

 aagh: LoanReceivedOnMarch0120231Member

 aagh: LoanReceivedOnMarch0120231Member

 aagh: LoanReceivedOnMarch0120231Member

 aagh: LoanReceivedOnMarch0120231Member

 aagh: LoanReceivedOnMarch0120232Member

 aagh: LoanReceivedOnMarch0120232Member

 aagh: LoanReceivedOnMarch0120232Member

 aagh: LoanReceivedOnMarch0120232Member

 aagh: LoanReceivedOnMarch0120233Member

 aagh: LoanReceivedOnMarch0120233Member

 aagh: LoanReceivedOnMarch0120233Member

 aagh: LoanReceivedOnMarch0120233Member

 us-gaap: LoansPayableMember

 us-gaap: LoansPayableMember

 2021-09-30
 2021-09-30

 aagh: LoanReceivedOnApril272021Member

 aagh: LoanReceivedOnApril272021Member

 aagh: LoanReceivedOnJune32021Member

 aagh: LoanReceivedOnJune32021Member

 aagh: LoanReceivedOnJune42021Member

 aagh: LoanReceivedOnJune42021Member

 aagh: LoanReceivedOnJune232021Member

 aagh: LoanReceivedOnJune232021Member

 aagh: LoanReceivedOnJuly122021Member

 aagh: LoanReceivedOnJuly122021Member

 aagh: LoanReceivedOnSeptember12021Member

 aagh: LoanReceivedOnSeptember12021Member

 aagh: LoanReceivedOnSeptember222021Member

 aagh: LoanReceivedOnSeptember222021Member

 aagh: LoanReceivedOnSeptember272021Member

 aagh: LoanReceivedOnSeptember272021Member

 aagh: LoanReceivedOnOctober292021Member

 aagh: LoanReceivedOnOctober292021Member

 aagh: LoanReceivedOnNovember92021Member

 aagh: LoanReceivedOnNovember92021Member

 aagh: LoanReceivedOnNovember162021Member

 aagh: LoanReceivedOnNovember162021Member

 aagh: LoanReceivedOnNovember182021Member

 aagh: LoanReceivedOnNovember182021Member

 aagh: LoanReceivedOnNovember292021Member

 aagh: LoanReceivedOnNovember292021Member

 aagh: LoanReceivedOnNovember302021Member

 aagh: LoanReceivedOnNovember302021Member

 aagh: LoanReceivedOnOctober132022Member

 aagh: LoanReceivedOnOctober132022Member

 aagh: LoanReceivedOnMarch102023Member

 aagh: LoanReceivedOnMarch102023Member

 aagh: LoanReceivedOnMarch142023Member

 aagh: LoanReceivedOnMarch142023Member

 aagh: LoanReceivedOnMarch162023Member

 aagh: LoanReceivedOnMarch162023Member

 aagh: LoanReceivedOnApril172023Member

 aagh: LoanReceivedOnApril172023Member

 aagh: LoanReceivedOnMay92023Member

 aagh: LoanReceivedOnMay92023Member

 aagh: LoanReceivedOnJune242021Member

 aagh: LoanReceivedOnJune242021Member

 2025-06-30

 2024-07-01
 2025-06-30

 2026-12-31

 2025-07-01
 2026-12-31

 2027-12-31

 2026-07-01
 2027-12-31

 2028-12-31

 2027-07-01
 2028-12-31

 us-gaap: SeriesAPreferredStockMember

 2016-06-30

 us-gaap: SeriesAPreferredStockMember

 2015-07-01
 2016-06-30

 us-gaap: SeriesAPreferredStockMember

 2016-08-31

 aagh: TopProfessionalManagementGroupIncMember

 aagh: ImediplusIncMember

 aagh: ImediplusIncMember

 2022-03-31
 2022-03-31

 2022-03-31

 2023-11-22
 2023-11-22

 2023-11-22

 2023-11-24
 2023-11-24

 2023-11-24

 2024-01-02
 2024-01-02

 2024-01-02

 2024-01-16
 2024-01-16

 2024-01-16

 aagh: TopProfessionalManagementGroupIncMember

 2023-10-30
 2023-10-30

 2023-10-30

 us-gaap: ForeignCountryMember

 us-gaap: DomesticCountryMember

 us-gaap: DomesticCountryMember

 us-gaap: ForeignCountryMember

 us-gaap: ForeignCountryMember

 srt: MinimumMember
 aagh: GKTAlhambraLPMember

 srt: MinimumMember
 aagh: SoCalIndustrialLLCMember

 2024-08-26
 2024-08-26

 aagh: SecondAndThirdYearMember

 2024-08-26
 2024-08-26

 2024-08-09
 2024-09-15

 2024-10-30
 2024-10-30

 2024-09-20
 2024-09-20